var title_f9_49_10000="Rotavirus effectiveness";
var content_f9_49_10000=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58821&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58821&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 611px\">",
"   <div class=\"ttl\">",
"    Percentage of rotavirus tests with positive results, by surveillance week - participating laboratories, National Respiratory and Enteric Virus Surveillance System (NREVSS), United States, July 2000-June 2009*",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 591px; height: 312px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * A median of 67 laboratories (range: 62-72) contributed rotavirus testing data to NREVSS during July 2000-June 2009.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Range created using the maximum or minimum percentage of rotavirus-positive tests for each surveillance week during 2000-2006. Maximums and minimums for each week might have occurred during any of the six rotavirus seasons during 2000-2006.",
"      <br>",
"       &Delta; The onset of rotavirus season was defined as the first of two consecutive weeks during which the percentage of stool specimens testing positive for rotavirus was &ge;10 percent; offset was defined as the last of two consecutive weeks during which the percentage of stool specimens testing positive for rotavirus was &ge;10 percent.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reduction in rotavirus after vaccine introduction--United States, 2000-2009. MMWR Morb Mortal Wkly Rep 2009; 58:1146.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_49_10000=[""].join("\n");
var outline_f9_49_10000=null;
var title_f9_49_10001="Tricyclic ECG changes B";
var content_f9_49_10001=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F76352&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F76352&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 544px\">",
"   <div class=\"ttl\">",
"    Electrocardiographic changes associated with tricyclic antidepressant overdose",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 524px; height: 350px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Following treatment with sodium bicarbonate, the intraventricular conduction delay resolves, and the QRS complex duration and morphology return to normal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_49_10001=[""].join("\n");
var outline_f9_49_10001=null;
var title_f9_49_10002="Thigh sleeve PI";
var content_f9_49_10002=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F83481&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F83481&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Thigh sleeve",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Wearing a thigh sleeve (the blue fabric band around the thigh) can help ease symptoms of a muscle strain.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_49_10002=[""].join("\n");
var outline_f9_49_10002=null;
var title_f9_49_10003="Pyrantel pamoate: Pediatric drug information";
var content_f9_49_10003=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Pyrantel pamoate: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?3/62/4068?source=see_link\">",
"    see \"Pyrantel pamoate: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?3/4/3140?source=see_link\">",
"    see \"Pyrantel pamoate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F215699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Pin-X&reg; [OTC];",
"     </li>",
"     <li>",
"      Reese's Pinworm Medicine [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F215700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Combantrin&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1049568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anthelmintic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1049560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?3/62/4068?source=see_link\">",
"      see \"Pyrantel pamoate: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children and Adults: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Roundworm, pinworm, or trichostrongyliasis: 11 mg pyrantel base/kg administered as a single dose; maximum dose: 1 g; dosage should be repeated after 2 weeks for pinworm infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hookworm: 11 mg pyrantel base/kg/day once daily for 3 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maximum daily dose: 1 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Moniliformis infection: 11 mg pyrantel base/kg as a single dose; repeat this dose twice at 2-week intervals",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F215686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral, as pamoate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pin-X&reg;: 144 mg/mL (30 mL, 60 mL) [sugar free; contains sodium benzoate; caramel flavor; equivalent to pyrantel base 50 mg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Reese's Pinworm Medicine: 144 mg/mL (30 mL, 60 mL, 240 mL) [equivalent to pyrantel base 50 mg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, chewable, oral, as pamoate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pin-X&reg;: 720.5 mg [scored; contains aspartame; equivalent to pyrantel base 250 mg]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F215671\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1049571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: May be mixed with milk or fruit juice. May be administered without regard to meals. Purgation is not required prior to, during, or after use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Suspension: Shake well before use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: Chewable tablet must be chewed thoroughly before swallowing.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1049563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature. Protect from light.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1049570\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Roundworm (",
"     <i>",
"      Ascaris lumbricoides",
"     </i>",
"     ), pinworm (",
"     <i>",
"      Enterobius vermicularis",
"     </i>",
"     ), and hookworm (",
"     <i>",
"      Ancylostoma duodenale",
"     </i>",
"     and",
"     <i>",
"      Necator americanus",
"     </i>",
"     ) infestations; trichostrongyliasis and moniliformis infections",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F215731\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal cramps, diarrhea, nausea, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1049574\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to pyrantel pamoate or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1049559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with liver impairment, anemia, malnutrition. The chewable tablet contains aspartame which is metabolized to phenylalanine and must be avoided or used with caution in patients with phenylketonuria.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1049558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pin-X&reg; contains sodium benzoate; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse; avoid use of pyrantel pamoate products containing sodium benzoate in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate displaces bilirubin from protein binding sites",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F215680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoquinolines (Antimalarial): May decrease the serum concentration of Anthelmintics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13761484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pyrantel pamoate has minimal systemic absorption. Systemic absorption would be required in order for pyrantel pamoate to cross the placenta and reach the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1049567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stool for presence of eggs, worms, and occult blood; serum AST and ALT",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1049557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Promotes release of acetylcholine and inhibits cholinesterase causing neuromuscular paralysis of susceptible helminths",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1049573\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Poor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Undergoes partial hepatic metabolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Within 1-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: In feces (50% as unchanged drug) and urine (7% as unchanged drug and metabolites)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1049565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?3/4/3140?source=see_link\">",
"      see \"Pyrantel pamoate: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hygienic precaution is essential to prevent reinfection. Disinfect toilets; change and wash underclothes, bed linens, towels, and clothes daily. Wash your hands with soap often, especially before eating and after using the toilet. Do not scratch the infected area or place your fingers in your mouth. May cause dizziness or drowsiness and impair ability to perform activities requiring mental alertness or physical coordination.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12750 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-89.32.226.102-9F539080E8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_49_10003=[""].join("\n");
var outline_f9_49_10003=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215699\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215700\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049568\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049560\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215686\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215671\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049571\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049563\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049570\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215731\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049574\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049559\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049558\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299963\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215680\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13761484\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049567\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049557\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049573\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049565\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12750\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12750|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?3/62/4068?source=related_link\">",
"      Pyrantel pamoate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?3/4/3140?source=related_link\">",
"      Pyrantel pamoate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_49_10004="Dyshidrotic eczema mild 2";
var content_f9_49_10004=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F82781&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F82781&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Dyshidrotic eczema of the hands",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_49_10004=[""].join("\n");
var outline_f9_49_10004=null;
var title_f9_49_10005="Pelvic AP compression fracture type";
var content_f9_49_10005=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F51376&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F51376&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 546px\">",
"   <div class=\"ttl\">",
"    Pelvic AP compression fracture: Type III",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 526px; height: 404px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Three images of a Type III AP compression fracture: (A) Schematic; (B) AP radiograph; (C) CT scan.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sagi C. Lower extremity: Pelvic ring fractures. In: Rockwood and Green's Fractures in Adults,&nbsp;7th ed, Bucholz RW, Court-Brown CM, Heckman JD, Tornetta P (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_49_10005=[""].join("\n");
var outline_f9_49_10005=null;
var title_f9_49_10006="Bronchogenic spread PA";
var content_f9_49_10006=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F66519&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F66519&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Disseminated bronchioloalveolar cell carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 355px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple ill-defined nodular tumor foci, likely resulting from bronchogenic spread.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_49_10006=[""].join("\n");
var outline_f9_49_10006=null;
var title_f9_49_10007="Management of pain in patients with cirrhosis";
var content_f9_49_10007=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of pain in patients with cirrhosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/49/10007/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/49/10007/contributors\">",
"     James P Hamilton, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/49/10007/contributors\">",
"     Eric Goldberg, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/49/10007/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/49/10007/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/49/10007/contributors\">",
"     Bruce A Runyon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/49/10007/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/49/10007/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/49/10007/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with liver disease may develop acute or chronic pain from a variety of causes. In addition to causes common in the otherwise healthy population, those with advanced liver disease may have ascites (leading to abdominal and lower back pain) and gynecomastia (leading to mastalgia).",
"   </p>",
"   <p>",
"    Management of pain in patients with liver disease raises special concerns. The choice of appropriate analgesic agents requires a thorough understanding of their pharmacokinetic and side effect profiles.",
"   </p>",
"   <p>",
"    As a general rule, patients with mild liver disease can be treated with a similar choice of drugs as those who are otherwise healthy. Susceptibility to adverse effects increases with worsening liver function due to altered pharmacokinetics and hemodynamic changes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/22/22889?source=see_link\">",
"     \"Tests of the liver's capacity to transport organic anions and metabolize drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The exact cutoff at which drug doses and the selection of drugs should be altered is uncertain. Modifications of drug-prescribing should generally be considered in patients who have developed cirrhosis, particularly when accompanied by portal hypertension (such as those with esophageal varices, ascites, or portal",
"    <span class=\"nowrap\">",
"     gastropathy/colopathy)",
"    </span>",
"    or renal insufficiency. Important exceptions are patients who are actively drinking alcohol and those on multiple medications, who can develop severe hepatotoxicity from concomitant use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    regardless of the severity of liver disease.",
"   </p>",
"   <p>",
"    This topic review will summarize safety considerations of nonselective nonsteroidal antiinflammatory drugs (NSAIDs) selective NSAIDs (COX-2 inhibitors), opioids, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    in patients with cirrhosis. A general approach to patients with cirrhosis is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17337?source=see_link\">",
"     \"Overview of the complications, prognosis, and management of cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NONSELECTIVE NSAIDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;NSAIDs are associated with an increased risk of variceal hemorrhage, impaired renal function, and the development of diuretic resistant ascites. Thus, NSAIDs (including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ) should generally be avoided in patients with cirrhosis.",
"   </p>",
"   <p>",
"    The primary effect of NSAIDs is to inhibit cyclooxygenase (prostaglandin synthase), thereby impairing the ultimate transformation of arachidonic acid to prostaglandins, prostacyclin, and thromboxanes. Two related isoforms of the cyclooxygenase (COX) enzyme have been described: COX-1 and COX-2. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1336?source=see_link\">",
"     \"NSAIDs: Mechanism of action\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Gastrointestinal toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;NSAIDs inhibit the production of prostaglandins involved in the protection of the gastrointestinal mucosa from noxious agents such as gastric acid. They also inhibit the production of thromboxane leading to decreased platelet aggregation and impaired hemostasis. Multiple studies have demonstrated that patients who take",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    or other NSAIDs are at least three times as likely to have severe gastrointestinal bleeding from peptic ulcers compared with patients who do not take NSAIDs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6745?source=see_link\">",
"     \"NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This risk may be further increased in patients who have an underlying coagulopathy such as occurs in those with advanced cirrhosis.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    alone, or in conjunction with other NSAIDs has been associated with variceal bleeding. In one case-control study, patients with variceal bleeding were 2.8 times as likely to have used NSAIDs in the week prior to the bleed compared with patients with cirrhosis with esophageal varices who had not bled [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10007/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Renal toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonsteroidal antiinflammatory drugs (NSAIDs) can induce two different forms of acute renal failure: hemodynamically-mediated and acute interstitial nephritis (which is often accompanied by the nephrotic syndrome). The former and perhaps the latter are directly related to the reduction in prostaglandin synthesis induced by the NSAID. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24582?source=see_link\">",
"     \"NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although renal prostaglandins are primarily vasodilators, they do not have a major role in the regulation of renal hemodynamics in healthy subjects, since the basal rate of prostaglandin synthesis is relatively low. By contrast, the release of these hormones (particularly prostacyclin and prostaglandin E2) is increased by underlying glomerular disease, renal insufficiency, hypercalcemia, and the vasoconstrictors angiotensin II and norepinephrine. The secretion of the latter hormones is increased in states of effective volume depletion, such as cirrhosis, heart failure, and true volume depletion due to gastrointestinal or renal salt and water losses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24582?source=see_link\">",
"     \"NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The adverse effect of NSAIDs on renal function in cirrhotic patients has been demonstrated in multiple studies (",
"    <a class=\"graphic graphic_figure graphicRef78038 \" href=\"UTD.htm?10/25/10653\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10007/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. In one study, patients given 50 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"     indomethacin",
"    </a>",
"    every six hours for one day had a 19 percent reduction in GFR and 23 percent reduction in renal plasma flow [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10007/abstract/3\">",
"     3",
"    </a>",
"    ]. Furthermore, there was a 29 percent increase in serum creatinine. Another study examined the effect of indomethacin on renal function in patients with Child-Pugh class A cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10007/abstract/4\">",
"     4",
"    </a>",
"    ]. Significant reductions in GFR, urinary sodium, urinary output, and renal plasma flow were observed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Effect on ascites management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another concern related to use of NSAIDs in patients with cirrhosis is that they diminish the natriuretic effects of diuretics in patients with ascites leading to impaired free water clearance and worsening of ascites and edema. Use of NSAIDs should be considered when evaluating patients with apparent diuretic-resistant ascites. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/40/35465?source=see_link\">",
"     \"Treatment of diuretic-resistant ascites in patients with cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     COX-2 INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selective COX-2 inhibitors are effective analgesics, which are associated with a decreased incidence of gastrointestinal and renal toxicity. However, they have been associated with an increased incidence of adverse cardiovascular events. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39351?source=see_link\">",
"     \"COX-2 selective inhibitors: Adverse cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In rat models of cirrhosis and ascites, selective COX-2 inhibitors caused significantly less decline in GFR, urine volume, and free water clearance than a nonselective COX inhibitor [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10007/abstract/5\">",
"     5",
"    </a>",
"    ]. However, rats given the COX-2 inhibitor still had nearly a 25 percent decrease in urine volume and a 20 percent decline in GFR from baseline.",
"   </p>",
"   <p>",
"    Experience with COX-2 inhibitors in patients with cirrhosis is limited. The largest study in humans included 28 patients with cirrhosis and ascites who were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    (200 mg every 12 hours for a total of five doses),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/43/43705?source=see_link\">",
"     naproxen",
"    </a>",
"    (500 mg every 12 hours for a total of five doses), or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10007/abstract/6\">",
"     6",
"    </a>",
"    ]. A significant reduction in glomerular filtration rate, renal plasma flow, urinary prostaglandin E2 excretion, and suppression of the diuretic and natriuretic response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    was observed in the group receiving naproxen but not celecoxib or placebo. Furthermore, naproxen but not celecoxib or placebo significantly inhibited platelet aggregation. The authors concluded that celecoxib may be a reasonable option for antiinflammatory treatment of patients with cirrhosis.",
"   </p>",
"   <p>",
"    However, the study evaluated only short-term treatment, involved only a small number of patients, and, as noted above,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    has the potential to decrease glomerular filtration rate compared with baseline. Further studies are needed to address the use of COX-2 inhibitors in patients with cirrhosis. At present, we advise against using these agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     OPIOIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Opioids should be used cautiously in patients with cirrhosis.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"     Fentanyl",
"    </a>",
"    appears to be safe in patients with modest hepatic dysfunction.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     Morphine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/34/10792?source=see_link\">",
"     oxycodone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/48/25353?source=see_link\">",
"     hydromorphone",
"    </a>",
"    should be used at reduced doses and prolonged intervals of administration.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/50/42792?source=see_link\">",
"     Tramadol",
"    </a>",
"    may be safe but experience is limited and thus it should not be used in those with advanced cirrhosis. The effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/0/35848?source=see_link\">",
"     codeine",
"    </a>",
"    are difficult to predict and therefore alternatives should be considered. Chronic administration of any opioid may lead to tolerance requiring escalating doses and therefore an increasing risk of hepatic encephalopathy.",
"   </p>",
"   <p>",
"    A variety of opioids are used for pain control. Opioids exert their analgesic effect through at least four groups of receptors, and probably other subpopulations as well. The distribution of these receptors throughout the body, along with their tissue densities within numerous organ systems, account for the global and varied effects of these drugs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42778?source=see_link\">",
"     \"Overview of the treatment of chronic pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As a general rule, these medications are metabolized through hepatic oxidation and glucuronidation. The clearance of opioids depends upon plasma protein binding, hepatic blood flow, and hepatic enzyme capacity. Oxidative enzyme pathways and opioids clearance are impaired in cirrhosis, which may lead to the accumulation of toxic metabolites [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10007/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       Morphine",
"      </a>",
"      undergoes rapid glucuronidation in the liver with subsequent systemic metabolism. Although glucuronidation is usually preserved despite diminished liver function, multiple studies have demonstrated that the clearance of morphine is delayed in patients with cirrhosis by 35 to 60 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?9/49/10007/abstract/7,9-11\">",
"       7,9-11",
"      </a>",
"      ]. In addition, morphine has increased oral bioavailability in cirrhotics secondary to reduced first pass hepatic metabolism [",
"      <a class=\"abstract\" href=\"UTD.htm?9/49/10007/abstract/7,11\">",
"       7,11",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      As a result, morphine must be used with caution in cirrhosis to avoid accumulation. A twofold increase in the interval of administration has been recommended [",
"      <a class=\"abstract\" href=\"UTD.htm?9/49/10007/abstract/9\">",
"       9",
"      </a>",
"      ]. Furthermore, if oral forms of morphine are to be used, the dose must be decreased to account for the increased bioavailability. In a cirrhotic patient with concomitant renal failure, morphine should be avoided as an accumulation of hydrophilic metabolites can lead to seizure activity, respiratory depression, and hepatic encephalopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?9/49/10007/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/44/11976?source=see_link\">",
"       Meperidine",
"      </a>",
"      is an opioid used primarily for conscious sedation. It is metabolized extensively in the liver and its clearance is significantly affected by hepatic dysfunction. In patients with cirrhosis, the plasma clearance is diminished by 50 percent and the half life doubles after a single intravenous dose of 0.8",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?9/49/10007/abstract/13,14\">",
"       13,14",
"      </a>",
"      ]. Thus, the dose in patients with cirrhosis should be decreased initially by 50 percent, with a lengthening of the time interval to re-administration.",
"     </li>",
"     <li>",
"      Other opioids that are metabolized by oxidative systems also have decreased clearance. This has been demonstrated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/44/11976?source=see_link\">",
"       meperidine",
"      </a>",
"      , propoxyphene, alfentanyl, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/50/42792?source=see_link\">",
"       tramadol",
"      </a>",
"      . Similar to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      , these drugs have increased bioavailability in patients with cirrhosis [",
"      <a class=\"abstract\" href=\"UTD.htm?9/49/10007/abstract/12\">",
"       12",
"      </a>",
"      ]. Thus, repeated administration of these drugs can lead to unwanted accumulation of the drug and its metabolites.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/0/35848?source=see_link\">",
"       Codeine",
"      </a>",
"      requires the oxidative enzyme capacity of the liver to convert it to its active metabolites potentially decreasing its effectiveness in patients with cirrhosis.",
"     </li>",
"     <li>",
"      Similarly,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/50/42792?source=see_link\">",
"       tramadol",
"      </a>",
"      requires conversion to O-demethyl-tramadol by hepatic oxidation so the analgesic effects of this drug may be unpredictable [",
"      <a class=\"abstract\" href=\"UTD.htm?9/49/10007/abstract/7\">",
"       7",
"      </a>",
"      ]. However, some hepatologists have had favorable experiences with tramadol in patients with cirrhosis in whom",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      was not effective.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"       Fentanyl",
"      </a>",
"      is a lipid soluble synthetic opioid that is about 80 to 100 times as potent as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      . It is converted by hydroxylation and deakylation in the liver into inactive and nontoxic metabolites. In a study of patients with histologically confirmed cirrhosis, the pharmacokinetics of fentanyl were unchanged when compared to healthy subjects [",
"      <a class=\"abstract\" href=\"UTD.htm?9/49/10007/abstract/15\">",
"       15",
"      </a>",
"      ]. However, the diseased patients in this study had normal serum albumin and the prothrombin times were only slightly abnormal. It is not known if the metabolism of fentanyl is affected in patients with severe hepatic dysfunction.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/34/10792?source=see_link\">",
"       Oxycodone",
"      </a>",
"      is a derivative of opium that has similar opioid effects to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      . Oxycodone is metabolized in the liver and excreted by the kidneys. A study of 24 patients with mild to moderate hepatic dysfunction showed that peak plasma concentrations of oxycodone were 50 percent greater compared to those in healthy controls [",
"      <a class=\"abstract\" href=\"UTD.htm?9/49/10007/abstract/16\">",
"       16",
"      </a>",
"      ]. In addition the t",
"      <span class=\"nowrap\">",
"       1/2",
"      </span>",
"      elimination for oxycodone was increased by 2.3 hours. Oxycodone should be used with caution in patients with cirrhosis, and if used, it should be administered at reduced doses and prolonged dosing intervals.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/48/25353?source=see_link\">",
"       Hydromorphone",
"      </a>",
"      is a hydrogenated ketone of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      that is metabolized by the liver. This opiate lacks toxic metabolites, but it is about five times stronger than morphine. In patients with cirrhosis, the elimination of hydromorphone is impaired and the half life is prolonged. Hydromorphone, like",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/34/10792?source=see_link\">",
"       oxycodone",
"      </a>",
"      , should be used with caution in patients with cirrhosis, and if used, it should be administered at reduced doses and prolonged dosing intervals [",
"      <a class=\"abstract\" href=\"UTD.htm?9/49/10007/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/57/36761?source=see_link\">",
"       Methadone",
"      </a>",
"      is a long acting opioid that is frequently used to treat heroin addiction. In a study of patients with mild to moderate cirrhosis, the pharmacokinetic profiles of methadone were unchanged compared to healthy individuals [",
"      <a class=\"abstract\" href=\"UTD.htm?9/49/10007/abstract/17\">",
"       17",
"      </a>",
"      ]. Although the half life of methadone in patients with severe cirrhosis can be mildly prolonged, drug disposition is not significantly altered [",
"      <a class=\"abstract\" href=\"UTD.htm?9/49/10007/abstract/17\">",
"       17",
"      </a>",
"      ]. Thus, methadone appears to be safe in patients with cirrhosis at least for short-term administration.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ACETAMINOPHEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is crucial to dismiss the misconception that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    should be strictly avoided in patients with liver disease. Acetaminophen is an effective and safe analgesic for patients with chronic liver disease when used at low doses provided that they do not actively drink alcohol. It is recommended routinely for patients undergoing interferon-based treatment for chronic hepatitis B or C. For patients with chronic active alcohol ingestion and cirrhosis, acetaminophen may be used at a maximum of 2 grams per day, which is one-half of the recommended daily dose. Although some studies show 4 grams of acetaminophen per day to be safe in patients with cirrhosis who are not actively consuming alcohol, the authors recommend no more than 2 grams per day to stay well below toxicity levels.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     Acetaminophen (paracetamol)",
"    </a>",
"    is a widely available over-the-counter medication used for analgesic and antipyretic purposes. It is well established to be hepatotoxic in large doses. When ingested in suicide attempts at doses greater than 10 grams, it causes severe hepatic necrosis and fulminant hepatic failure. Doses of less than 6 grams per day are considered non-toxic and the recommended upper limit for use is 4 grams per day. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/43/25274?source=see_link\">",
"     \"Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     Acetaminophen",
"    </a>",
"    appears to be safe in patients with cirrhosis when used at the recommended doses. In one study, six patients with chronic liver disease were given 4 grams per day for five days [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10007/abstract/18\">",
"     18",
"    </a>",
"    ]. There was no evidence of drug accumulation or hepatotoxicity in these subjects. In another trial by the same author, 20 patients with cirrhosis were given 4 grams per day for 13 days [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10007/abstract/19\">",
"     19",
"    </a>",
"    ]. Only one patient developed abnormal liver enzymes. After the labs returned to normal, the same patient was subsequently challenged with 10 and 14 day courses of 4 grams per day of acetaminophen without incident. It was felt that the earlier biochemical deterioration in this patient was not related to acetaminophen use.",
"   </p>",
"   <p>",
"    Patients that chronically abuse alcohol (even those without cirrhosis) should use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    with extreme caution. In healthy subjects, only a fraction of acetaminophen is metabolized by the cytochrome P-450 enzyme system to NAPQI. In patients who chronically abuse alcohol, the P450 system is induced and therefore more of the toxic metabolite NAPQI is generated. The hepatotoxicity of NAPQI is diminished by glutathione conjugation. However, alcoholic patients have reduced stores of glutathione secondary to impaired production and poor nutritional status.",
"   </p>",
"   <p>",
"    These factors lead to an increased likelihood of chronic alcohol abusers developing hepatotoxicity with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    use. A retrospective analysis of 67 patients described as regular users of alcohol who developed hepatic injury after acetaminophen ingestion showed that 60 percent of the patients took less than 6 grams per day; 40 percent of these patients took less than 4 grams per day [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10007/abstract/19\">",
"     19",
"    </a>",
"    ]. The majority of patients (90 percent) had AST levels ranging from 3000 to 48000 IU indicating severe hepatic necrosis, and 20 percent overall died [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10007/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, conflicting data have also been published suggesting that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    use is safe for alcoholics when used in recommended doses. In a randomized, double-blind, placebo-controlled study, 102 alcoholic patients were given 4 grams per day for two days [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10007/abstract/20\">",
"     20",
"    </a>",
"    ]. There was no elevation in aminotransferases compared with the placebo group. Unfortunately, there are serious limitations when interpreting these data. First, patients were in an inpatient alcohol detoxification program and were therefore not actively drinking when using acetaminophen. Second, it was not clear whether patients had advanced liver disease (which may have made them more predisposed to liver injury); that patients were excluded who had an international normalized ratio of &gt;1.5 suggested that hepatic synthetic function was relatively preserved. Thus, these data may not be applicable to cirrhotic patients who are actively drinking alcohol.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     COMBINATION FORMULATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many prescription and over the counter remedies are offered as combination preparations. As an example, Percocet is a combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/51/9016?source=see_link\">",
"     oxycodone-acetaminophen",
"    </a>",
"    .",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     Acetaminophen",
"    </a>",
"    can also be found in cold and flu remedies such as Nyquil, Alka-Seltzer Plus and Theraflu. Clinicians need to use caution when prescribing combination formulations because of the potential for unwanted toxicity. Two Percocet tablets taken every four hours, for example, contain 3.9 grams of acetaminophen. This represents the upper limit for dosing acetaminophen. Patients may not be aware that Percocet contains acetaminophen, and may take acetaminophen in addition to Percocet. Patients with cirrhosis need to be warned to read medication labels carefully before starting any new medicine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As a general rule, patients with mild liver disease can be treated with a similar choice of drugs as those who are otherwise healthy. Susceptibility to adverse effects increases with worsening liver function due to altered pharmacokinetics and hemodynamic changes. While the exact cutoff at which drug doses and the selection of drugs should be altered is uncertain, modifications of drug-prescribing should generally be considered in patients who have developed cirrhosis, particularly when accompanied by portal hypertension (such as those with esophageal varices, ascites, or portal",
"      <span class=\"nowrap\">",
"       gastropathy/colopathy)",
"      </span>",
"      or renal insufficiency. Important exceptions are patients who are actively drinking alcohol, who can develop severe hepatotoxicity from concomitant use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      regardless of the severity of liver disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The choice of appropriate analgesic agents in patients with cirrhosis requires a thorough knowledge of their pharmacokinetics and side effect profiles.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       Acetaminophen",
"      </a>",
"      is an effective and safe analgesic for patients with chronic liver disease when used at low doses. For patients with ongoing alcohol ingestion and cirrhosis, acetaminophen may be used at a maximum of 2 grams per day, which is one-half of the recommended daily dose. Although some studies show 4 grams of acetaminophen per day to be safe in patients with cirrhosis who are not actively consuming alcohol, the authors recommend no more than 2 grams per day to stay well below toxicity levels. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Acetaminophen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Many prescription and over the counter remedies are offered as combination preparations. Patients with cirrhosis need to be warned to read medication labels carefully before starting any new medicine to avoid accidental overdose. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Combination formulations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nonsteroidal antiinflammatory drugs (NSAIDs) are associated with an increased risk of variceal hemorrhage, impaired renal function, and the development of diuretic resistant ascites. Thus, NSAIDs (including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      ) should generally be avoided in patients with cirrhosis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Nonselective NSAIDs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Selective COX-2 inhibitors are effective analgesics that are associated with a decreased incidence of gastrointestinal and renal toxicity and an increased incidence of cardiovascular events. Experience in patients with cirrhosis is limited. At present, we advise against using these agents. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'COX-2 inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Opioids should be used cautiously in patients with cirrhosis.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/52/38730?source=see_link\">",
"       Fentanyl",
"      </a>",
"      appears to be safe in patients with modest hepatic dysfunction.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       Morphine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/34/10792?source=see_link\">",
"       oxycodone",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/48/25353?source=see_link\">",
"       hydromorphone",
"      </a>",
"      should be used at reduced doses and prolonged intervals of administration.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/50/42792?source=see_link\">",
"       Tramadol",
"      </a>",
"      may be safe but experience is limited. The effects of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/0/35848?source=see_link\">",
"       codeine",
"      </a>",
"      are difficult to predict and therefore alternatives should be considered. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Opioids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Strong consideration should be given to referring patients who require long-term analgesics to a pain management program.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10007/abstract/1\">",
"      De L&eacute;dinghen V, Heresbach D, Fourdan O, et al. Anti-inflammatory drugs and variceal bleeding: a case-control study. Gut 1999; 44:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10007/abstract/2\">",
"      Zipser RD, Hoefs JC, Speckart PF, et al. Prostaglandins: modulators of renal function and pressor resistance in chronic liver disease. J Clin Endocrinol Metab 1979; 48:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10007/abstract/3\">",
"      Boyer TD, Zia P, Reynolds TB. Effect of indomethacin and prostaglandin A1 on renal function and plasma renin activity in alcoholic liver disease. Gastroenterology 1979; 77:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10007/abstract/4\">",
"      Wong F, Massie D, Hsu P, Dudley F. Indomethacin-induced renal dysfunction in patients with well-compensated cirrhosis. Gastroenterology 1993; 104:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10007/abstract/5\">",
"      Bosch-Marc&egrave; M, Cl&agrave;ria J, Titos E, et al. Selective inhibition of cyclooxygenase 2 spares renal function and prostaglandin synthesis in cirrhotic rats with ascites. Gastroenterology 1999; 116:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10007/abstract/6\">",
"      Cl&agrave;ria J, Kent JD, L&oacute;pez-Parra M, et al. Effects of celecoxib and naproxen on renal function in nonazotemic patients with cirrhosis and ascites. Hepatology 2005; 41:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10007/abstract/7\">",
"      Tegeder I, L&ouml;tsch J, Geisslinger G. Pharmacokinetics of opioids in liver disease. Clin Pharmacokinet 1999; 37:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10007/abstract/8\">",
"      Chandok N, Watt KD. Pain management in the cirrhotic patient: the clinical challenge. Mayo Clin Proc 2010; 85:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10007/abstract/9\">",
"      Mazoit JX, Sandouk P, Zetlaoui P, Scherrmann JM. Pharmacokinetics of unchanged morphine in normal and cirrhotic subjects. Anesth Analg 1987; 66:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10007/abstract/10\">",
"      Crotty B, Watson KJ, Desmond PV, et al. Hepatic extraction of morphine is impaired in cirrhosis. Eur J Clin Pharmacol 1989; 36:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10007/abstract/11\">",
"      Hasselstr&ouml;m J, Eriksson S, Persson A, et al. The metabolism and bioavailability of morphine in patients with severe liver cirrhosis. Br J Clin Pharmacol 1990; 29:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10007/abstract/12\">",
"      Tegeder I, Geisslinger G, L&ouml;tsch J. [Therapy with opioids in liver or renal failure]. Schmerz 1999; 13:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10007/abstract/13\">",
"      Klotz U, McHorse TS, Wilkinson GR, Schenker S. The effect of cirrhosis on the disposition and elimination of meperidine in man. Clin Pharmacol Ther 1974; 16:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10007/abstract/14\">",
"      Pond SM, Tong T, Benowitz NL, et al. Presystemic metabolism of meperidine to normeperidine in normal and cirrhotic subjects. Clin Pharmacol Ther 1981; 30:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10007/abstract/15\">",
"      Haberer JP, Schoeffler P, Couderc E, Duvaldestin P. Fentanyl pharmacokinetics in anaesthetized patients with cirrhosis. Br J Anaesth 1982; 54:1267.",
"     </a>",
"    </li>",
"    <li>",
"     Physican's desk reference electronic library. Thomson. 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10007/abstract/17\">",
"      Novick DM, Kreek MJ, Arns PA, et al. Effect of severe alcoholic liver disease on the disposition of methadone in maintenance patients. Alcohol Clin Exp Res 1985; 9:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10007/abstract/18\">",
"      Benson GD. Acetaminophen in chronic liver disease. Clin Pharmacol Ther 1983; 33:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10007/abstract/19\">",
"      Zimmerman HJ, Maddrey WC. Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure. Hepatology 1995; 22:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10007/abstract/20\">",
"      Kuffner EK, Dart RC, Bogdan GM, et al. Effect of maximal daily doses of acetaminophen on the liver of alcoholic patients: a randomized, double-blind, placebo-controlled trial. Arch Intern Med 2001; 161:2247.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1236 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-B2700F0D78-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_49_10007=[""].join("\n");
var outline_f9_49_10007=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NONSELECTIVE NSAIDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Gastrointestinal toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Renal toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Effect on ascites management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      COX-2 INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      OPIOIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ACETAMINOPHEN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      COMBINATION FORMULATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/1236\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/1236|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/25/10653\" title=\"figure 1\">",
"      NSAID lowers GFR in cirrhosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/43/25274?source=related_link\">",
"      Acetaminophen (paracetamol) poisoning in adults: Pathophysiology, presentation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39351?source=related_link\">",
"      COX-2 selective inhibitors: Adverse cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/37/6745?source=related_link\">",
"      NSAIDs (including aspirin): Pathogenesis of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24582?source=related_link\">",
"      NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1336?source=related_link\">",
"      NSAIDs: Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/59/17337?source=related_link\">",
"      Overview of the complications, prognosis, and management of cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42778?source=related_link\">",
"      Overview of the treatment of chronic pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/22/22889?source=related_link\">",
"      Tests of the liver's capacity to transport organic anions and metabolize drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/40/35465?source=related_link\">",
"      Treatment of diuretic-resistant ascites in patients with cirrhosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_49_10008="Lentigo maligna melanoma 2";
var content_f9_49_10008=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F74664%7EDERM%2F54753&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F74664%7EDERM%2F54753&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lentigo maligna melanoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lentigo maligna melanoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lentigo maligna melanoma with a nodular component.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_49_10008=[""].join("\n");
var outline_f9_49_10008=null;
var title_f9_49_10009="Clinical features, diagnosis, and staging of newly diagnosed breast cancer";
var content_f9_49_10009=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical features, diagnosis, and staging of newly diagnosed breast cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/49/10009/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/49/10009/contributors\">",
"     Laura J Esserman, MD, MBA",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/49/10009/contributors\">",
"     Bonnie N Joe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/49/10009/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/49/10009/contributors\">",
"     Julie R Gralow, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/49/10009/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/49/10009/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/49/10009/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Globally, breast cancer is the most frequently diagnosed malignancy, accounting for over a million cases each year [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10009/abstract/1\">",
"     1",
"    </a>",
"    ]. It is also the leading cause of cancer death in women worldwide. In the United States, breast cancer is the most common female cancer, the second most common cause of cancer death in women, and the main cause of death in women ages 20 to 59 years [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10009/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once a diagnosis of breast cancer is established, it is important to accurately define the initial extent of disease since this information will affect treatment recommendations. This topic will review the clinical manifestations, diagnosis, differential diagnosis, and staging following a diagnosis of breast cancer.",
"   </p>",
"   <p>",
"    The factors that modify breast cancer risk, diagnostic evaluation of women with suspected breast cancer, the treatment approach to in situ and invasive breast cancer, and the use of prognostic and predictive factors in making adjuvant treatment decisions are covered separately.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28954?source=see_link\">",
"       \"Factors that modify breast cancer risk in women\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24138?source=see_link\">",
"       \"Diagnostic evaluation of women with suspected breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/28/43465?source=see_link\">",
"       \"Measurement of prognostic factors in breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/46/19177?source=see_link\">",
"       \"Overview of the treatment of newly diagnosed, non-metastatic breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/33/6680?source=see_link\">",
"       \"Breast ductal carcinoma in situ: Epidemiology, clinical manifestations, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/43/37561?source=see_link\">",
"       \"Ductal carcinoma in situ: Treatment and prognosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/51/17207?source=see_link\">",
"       \"Breast cancer during pregnancy and lactation: Epidemiology and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/36/26186?source=see_link\">",
"       \"Breast cancer in men\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H365148828\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast cancer is the most commonly diagnosed cancer worldwide with over 1,384,000 cases detected in 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10009/abstract/1\">",
"     1",
"    </a>",
"    ]. The",
"    <a class=\"external\" href=\"file://globocan.iarc.fr/factsheets/populations/factsheet.asp?uno=900\">",
"     incidence rates",
"    </a>",
"    are highest in North America,",
"    <span class=\"nowrap\">",
"     Australia/New",
"    </span>",
"    Zealand, and in western and northern Europe, and lowest in Asia and sub-Saharan Africa [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10009/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. These international differences are likely related to societal changes as a result of industrialization (eg, changes in fat intake, body weight, age at menarche,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lactation, and reproductive patterns such as fewer pregnancies and later age at first birth). Studies of migration patterns to the US are consistent with the importance of cultural",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    environmental changes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10009/abstract/4\">",
"     4",
"    </a>",
"    ]. In general, incidence rates of breast cancer are greater in second-generation migrants and increase further in third- and fourth- generation migrants.",
"   </p>",
"   <p>",
"    In the US, breast cancer accounts for over 230,000 cases each year and is responsible for over 40,000 deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10009/abstract/2\">",
"     2",
"    </a>",
"    ]. The incidence rates decreased from 1999 to 2007 by 1.8 percent per year [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10009/abstract/5\">",
"     5",
"    </a>",
"    ]. It is likely that two factors have contributed to this: the discontinuation of hormone replacement therapy (HRT) and the",
"    <span class=\"nowrap\">",
"     saturation/leveling",
"    </span>",
"    off of mammography rates [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10009/abstract/6-9\">",
"     6-9",
"    </a>",
"    ]. Of these factors, the discontinuation of HRT has probably had a greater effect [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10009/abstract/8,10,11\">",
"     8,10,11",
"    </a>",
"    ]. This was demonstrated in a report from the Women&rsquo;s Health Initiative where a rapid decline in breast cancer incidence was noted in trial participants following discontinuation of HRT [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10009/abstract/10\">",
"     10",
"    </a>",
"    ]. Discontinuation of HRT was not accompanied by changes in mammographic utilization, suggesting that the latter did not play a role in the decline in incidence rates. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=see_link&amp;anchor=H7#H7\">",
"     \"Postmenopausal hormone therapy: Benefits and risks\", section on 'Breast cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1749806335\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple factors are associated with an increased risk of breast cancer. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age and gender",
"     </li>",
"     <li>",
"      Race and ethnicity",
"     </li>",
"     <li>",
"      Benign breast disease",
"     </li>",
"     <li>",
"      Personal history of breast cancer",
"     </li>",
"     <li>",
"      Reproductive and hormonal factors",
"     </li>",
"     <li>",
"      Family history and genetic factors",
"     </li>",
"     <li>",
"      Exposure to ionizing radiation",
"     </li>",
"     <li>",
"      Environmental and lifestyle factors",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A more extensive discussion on risk factors is covered separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28954?source=see_link\">",
"     \"Factors that modify breast cancer risk in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1583245923\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of breast cancer requires histologic evaluation. The typical features of invasive breast cancer are reviewed below. Breast cancer screening methods in women not suspected of having breast cancer is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41754?source=see_link\">",
"     \"Screening for breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1749806644\">",
"    <span class=\"h2\">",
"     Signs and symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;In countries with established breast cancer screening programs, most patients present due to an abnormal mammogram. However, up to 15 percent of women are diagnosed with breast cancer due to the presence of a breast mass that is not detected on mammogram (mammographically occult disease), and another 30 percent present with a breast mass in the interval between mammograms (interval cancers) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10009/abstract/12\">",
"     12",
"    </a>",
"    ]. In addition, women without access to screening mammograms and younger women under 40 years who may not be undergoing routine screening mammograms may present with a breast or axillary mass with or without skin changes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H373972748\">",
"    <span class=\"h3\">",
"     Breast mass",
"    </span>",
"    &nbsp;&mdash;&nbsp;The &ldquo;classic&rdquo; characteristics of a cancerous lesion include a hard, immovable, single dominant lesion with irregular borders. However, these features cannot reliably distinguish a benign from a malignant tumor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24825?source=see_link\">",
"     \"Breast masses and other common breast problems\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24138?source=see_link\">",
"     \"Diagnostic evaluation of women with suspected breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H373972809\">",
"    <span class=\"h3\">",
"     Locally advanced disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The signs of more advanced locoregional disease include axillary adenopathy (suggesting locoregional disease), or skin findings such as erythema, thickening, or dimpling of the overlying skin (peau d&rsquo;orange), suggesting inflammatory breast cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/20/31048?source=see_link\">",
"     \"Inflammatory breast cancer: Clinical features and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H373972816\">",
"    <span class=\"h3\">",
"     Metastatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms of metastatic breast cancer depend on the organs involved, with the most common sites of involvement being the bone (eg, back or leg pain), liver (abdominal pain, nausea, jaundice), and lungs (eg, shortness of breath or cough). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/0/8202?source=see_link&amp;anchor=H5#H5\">",
"     \"Patterns of relapse and long-term complications of therapy in breast cancer survivors\", section on 'Metastatic disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1583246595\">",
"    <span class=\"h2\">",
"     Imaging findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classic mammographic findings of breast cancer include the presence of a soft tissue mass (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59883 \" href=\"UTD.htm?28/38/29295\">",
"     image 1",
"    </a>",
"    ) and clustered microcalcifications. The most specific feature is a spiculated soft tissue mass, with nearly 90 percent representing an invasive cancer. A more detailed discussion on the mammographic presentation of breast cancer is covered separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24138?source=see_link&amp;anchor=H5#H5\">",
"     \"Diagnostic evaluation of women with suspected breast cancer\", section on 'Mammographic features of breast cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Breast ultrasound is often used to distinguish a benign versus malignant lesion. Sonographic features of malignancy include the presence of spiculation, hypoechogenicity, microlobulation, internal calcifications, shadowing, a lesion taller than it is wide, and angular margins [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10009/abstract/13\">",
"     13",
"    </a>",
"    ]. A typical ultrasound of early breast cancer is depicted here (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52790 \" href=\"UTD.htm?15/24/15748\">",
"     image 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Magnetic resonance imaging (MRI) is typically used to screen women at high risk for breast cancer. Although nearly all invasive breast cancers enhance on gadolinium contrast-enhanced MRI, MRI is not specific enough to obviate the need for biopsy. MRI features of breast cancer include irregular or spiculated margins, rimlike enhancement, heterogenous internal enhancement, and enhancing internal septa (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef51605 \" href=\"UTD.htm?0/34/549\">",
"     image 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10009/abstract/14\">",
"     14",
"    </a>",
"    ]. Non-mass regional enhancement on contrast-enhanced MRI may also increase suspicion of an invasive lesion, particularly if the enhancement is associated with a focal lesion or exhibits segmental distribution [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10009/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/29/23002?source=see_link&amp;anchor=H10606358#H10606358\">",
"     \"MRI of the breast and emerging technologies\", section on 'Screening high risk women'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24138?source=see_link&amp;anchor=H11#H11\">",
"     \"Diagnostic evaluation of women with suspected breast cancer\", section on 'Breast MRI'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1583246042\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are various histologic types of breast carcinoma that differ in microscopic appearance and biologic behavior (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16040?source=see_link\">",
"     \"Pathology of breast cancer\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The most common histologic types of epithelial breast carcinoma are described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1583246092\">",
"    <span class=\"h3\">",
"     Infiltrating ductal carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infiltrating ductal carcinomas are the most common type of invasive breast cancer, accounting for 70 to 80 percent of invasive lesions. These lesions are characterized by cords and nests of cells with varying amounts of gland formation and cytologic features that range from bland to highly malignant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1583246099\">",
"    <span class=\"h3\">",
"     Infiltrating lobular carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infiltrating lobular carcinomas comprise about 8 percent of invasive breast cancers. Microscopically, they are characterized by small cells that insidiously infiltrate the mammary stroma and adipose tissue individually and in a single file pattern.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1583246106\">",
"    <span class=\"h3\">",
"     Mixed ductal/lobular carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;A mixed histologic appearance comprising of both ductal and lobular characteristics is defined as a mixed invasive carcinoma. These comprise 7 percent of invasive breast cancers.",
"   </p>",
"   <p>",
"    Other histologic types of breast cancer include metaplastic, mucinous, tubular, medullary, and papillary carcinomas. Together they account for less than 5 percent of invasive cancers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16040?source=see_link\">",
"     \"Pathology of breast cancer\"",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1583246291\">",
"    <span class=\"h2\">",
"     Molecular subtypes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on gene expression profiles the following molecular subtypes have been identified (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/21/41302?source=see_link\">",
"     \"Molecular intrinsic subtypes of breast cancer\"",
"    </a>",
"    ):",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1583246318\">",
"    <span class=\"h3\">",
"     Luminal subtypes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The luminal subtypes are characterized as luminal A and luminal B. They are the most common subtypes of breast cancer and make up the majority of ER-positive breast cancers. The name &ldquo;luminal&rdquo; derives from similarity in gene expression between these tumors and the luminal epithelium of the breast. They typically express cytokeratins 8 and 18.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1583246325\">",
"    <span class=\"h3\">",
"     HER2-enriched",
"    </span>",
"    &nbsp;&mdash;&nbsp;The HER2-enriched subtype makes up about 10 to 15 percent of breast cancers and is characterized by high expression of HER2 and proliferation gene clusters and low expression of the luminal and basal gene clusters. These tumors are often negative for ER and PR. Only half of clinical HER2-positive breast cancers are HER2 enriched on molecular profiling; the other half can include any molecular subtype, but is mostly made up of HER2-positive luminal subtypes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1583246332\">",
"    <span class=\"h3\">",
"     Basal subtypes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of these tumors fall under the category of triple-negative breast cancers because they are ER, PR and HER2 negative. Further discussion of subtypes of ER-negative breast cancers is covered separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/40/34441?source=see_link&amp;anchor=H493962740#H493962740\">",
"     \"Epidemiology, risk factors and the clinical approach to ER/PR negative, HER2-negative (Triple-negative) breast cancer\", section on 'Molecular classification of triple-negative breast cancer'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1749806798\">",
"    <span class=\"h1\">",
"     EVALUATION OF SUSPECTED DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging studies and a clinical breast exam cannot establish a diagnosis of cancer. They instead identify patients who require further evaluation, either with follow-up imaging or biopsy. The diagnosis of breast cancer requires obtaining a tissue sample and requires pathologic, radiologic, and clinical correlation (also known as the triple test). The diagnostic approach is outlined below (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24825?source=see_link&amp;anchor=H23#H23\">",
"     \"Breast masses and other common breast problems\", section on 'Biopsy'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women who present with abnormal imaging findings alone should undergo biopsy guided by mammography (stereotactic biopsy or wire localization breast biopsy), ultrasound, or breast MRI. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24504?source=see_link&amp;anchor=H3#H3\">",
"       \"Breast biopsy\", section on 'Stereotactic biopsy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24504?source=see_link&amp;anchor=H9#H9\">",
"       \"Breast biopsy\", section on 'Wire localization breast biopsy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24504?source=see_link&amp;anchor=H11#H11\">",
"       \"Breast biopsy\", section on 'MRI-guided breast biopsy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24504?source=see_link&amp;anchor=H4#H4\">",
"       \"Breast biopsy\", section on 'Core needle biopsy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Women presenting with a breast mass should undergo a fine needle aspiration or core needle biopsy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24504?source=see_link&amp;anchor=H2#H2\">",
"       \"Breast biopsy\", section on 'Fine needle aspiration biopsy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24504?source=see_link&amp;anchor=H4#H4\">",
"       \"Breast biopsy\", section on 'Core needle biopsy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In addition to a biopsy of the breast, women presenting with signs of inflammatory breast cancer (eg, rapidly progressing, tender, firm, and enlarged breast with thickening of the underlying skin) require two full thickness skin biopsies. The presence of dermal lymphatic invasion is pathognomonic for inflammatory breast cancer. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24504?source=see_link&amp;anchor=H12#H12\">",
"       \"Breast biopsy\", section on 'Skin punch biopsy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28333270\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of breast cancer is defined by the presence of malignant epithelial cells (carcinoma) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10009/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1749806805\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of breast cancer varies depending on the mode of presentation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H373972913\">",
"    <span class=\"h2\">",
"     Breast mass",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients presenting with a cystic or solid breast mass, the differential diagnosis includes malignant and benign lesions. A further discussion of the differential diagnosis of the breast mass is covered separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24825?source=see_link&amp;anchor=H18#H18\">",
"     \"Breast masses and other common breast problems\", section on 'Breast masses'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11081?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of benign breast disease\", section on 'Classification of benign breast lesions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1583247104\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of breast cancer based on abnormal imaging is guided by the Breast Imaging Reporting and Data System (BI-RADS) system, based on the relative likelihood of a normal, benign or malignant diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10009/abstract/16\">",
"     16",
"    </a>",
"    ]. The BI-RADS system is used to aid the interpretation of mammography, ultrasound, and breast MRI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39482?source=see_link&amp;anchor=H15#H15\">",
"     \"Breast imaging: Mammography and ultrasonography\", section on 'The BI-RADS categories'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H373972920\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women who undergo a biopsy, the pathologic differential diagnosis must include other breast lesions beyond invasive breast cancer. Given the heterogeneity in the presentation and pathologic features of invasive breast cancer, expertise in breast pathology is often required to distinguish invasive carcinoma from other breast lesions. Breast lesions that should be considered in the review of pathology include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ductal carcinoma in situ (DCIS) represents a heterogeneous group of pre-cancerous lesions confined to the breast ducts and lobules and is potentially a precursor lesion to invasive breast cancer. DCIS is characterized by the size of the lesion, nuclear grade, presence and extent of comedo necrosis, and architectural pattern. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/33/6680?source=see_link\">",
"       \"Breast ductal carcinoma in situ: Epidemiology, clinical manifestations, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Microinvasive breast cancer (or DCIS with microinvasion) typically presents as a palpable mass. On pathological examination, it is an invasive carcinoma of the breast where the largest focus is no more than 1 mm. It tends to be associated with high-grade DCIS and comedo-type necrosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/41/14998?source=see_link\">",
"       \"Microinvasive breast carcinoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Benign breast lesions, which can be categorized as non-proliferative, proliferative without atypia, or proliferative with atypia. A further discussion of benign breast disease is covered separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11081?source=see_link\">",
"       \"Overview of benign breast disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/60/4040?source=see_link&amp;anchor=H100217511#H100217511\">",
"       \"Breast cysts: Clinical manifestations, diagnosis, and management\", section on 'Diagnosis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/14/44265?source=see_link\">",
"       \"Atypia and lobular carcinoma in situ: High risk lesions of the breast\"",
"      </a>",
"      .).",
"     </li>",
"     <li>",
"      Other cancers &mdash; The breast can give rise to other invasive malignancies separate from primary breast cancer. These rare tumors include sarcoma, Paget disease, phyllodes tumor, and lymphoma. A biopsy is required to distinguish these tumors from primary breast cancer.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Breast sarcoma &mdash; Breast sarcomas are rare, histologically homogenous tumors that arise from the connective tissue within the breast. They can arise de novo, following radiation therapy, or in the context of lymphedema. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/3/28729?source=see_link\">",
"       \"Breast sarcoma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Paget disease &mdash; Paget disease of the breast typically presents as a raw, scaly, vesicular, or ulcerated lesion that begins on the nipple and spreads to the areola. Over 80 percent of cases are associated with an underlying breast cancer and are usually HER2 positive. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/0/14?source=see_link\">",
"       \"Paget disease of the breast\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Phyllodes tumors &mdash; Phyllodes tumors are uncommon fibroepithelial breast tumors that can behave in variable fashion, and are classified as benign, borderline, or malignant based on histologic criteria (cellular atypia, mitotic activity, margins, and stromal overgrowth).",
"     </li>",
"     <li>",
"      Lymphoma &mdash; Lymphoma of the breast typically presents as a painless unilateral breast mass in an older woman. The vast majority are non-Hodgkin lymphomas, most commonly of B-cell lineage. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/19/36150?source=see_link\">",
"       \"Breast lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1583246405\">",
"    <span class=\"h1\">",
"     POST-DIAGNOSIS EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;If cancer is identified, the breast tumor requires further evaluation for the status of breast cancer receptors. (See",
"    <a class=\"local\" href=\"#H1662781741\">",
"     'Breast cancer receptor testing'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In addition, patients should proceed with an appropriate staging work-up to determine extent of disease. Women presenting with signs or symptoms of metastatic breast cancer should undergo additional imaging; in addition, a biopsy of at least one metastatic lesion to confirm the diagnosis of metastatic breast cancer. (See",
"    <a class=\"local\" href=\"#H340693972\">",
"     'Role of imaging'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H2\">",
"     'Staging'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1662781741\">",
"    <span class=\"h2\">",
"     Breast cancer receptor testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Newly diagnosed breast cancers must be tested for by estrogen (ER) and progesterone (PR) receptor expression and for overexpression of human epidermal growth factor 2 (HER2) receptors. This information is critical for both prognostic and therapeutic purposes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/28/43465?source=see_link\">",
"     \"Measurement of prognostic factors in breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/46/19177?source=see_link\">",
"     \"Overview of the treatment of newly diagnosed, non-metastatic breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H856570592\">",
"    <span class=\"h3\">",
"     ER and PR",
"    </span>",
"    &nbsp;&mdash;&nbsp;ER and PR are prognostic factors for invasive breast cancer, particularly in the first five years following initial diagnosis. In addition, patients who are ER",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    PR positive are candidates for endocrine therapy as neoadjuvant or adjuvant treatment. ER-positivity is defined by immunohistochemistry (IHC) for ER and PR in more than one percent of tumor cells. More discussion on the use of",
"    <span class=\"nowrap\">",
"     ER/PR",
"    </span>",
"    in breast cancer is covered separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19194?source=see_link\">",
"     \"Hormone receptors in breast cancer: Clinical utility and guideline recommendations to improve test accuracy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/28/43465?source=see_link\">",
"     \"Measurement of prognostic factors in breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H856570599\">",
"    <span class=\"h3\">",
"     HER2",
"    </span>",
"    &nbsp;&mdash;&nbsp;HER2 overexpression is present in 20 percent of patients and predicts those who will benefit from HER2-directed therapy. HER2 overexpression is detected by uniform intense membrane staining of &gt;30 percent of invasive tumor cells (IHC 3+) or the presence of HER2 gene amplification by fluorescence in-situ hybridization (FISH) defined as a ratio of",
"    <span class=\"nowrap\">",
"     HER2/CEP17",
"    </span>",
"    (centromeric probe to chromosome 17) ratio &ge;2.0. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/22/30058?source=see_link&amp;anchor=H6#H6\">",
"     \"HER2 and predicting response to therapy in breast cancer\", section on 'Assays for HER2 expression'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/28/43465?source=see_link\">",
"     \"Measurement of prognostic factors in breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H856570606\">",
"    <span class=\"h3\">",
"     Frequency of subtypes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast cancer can be characterized into different subtypes by whether or not they express ER, PR, and HER2 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10009/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. The proportions of breast cancers with different receptor phenotypes were evaluated in one study of 61,309 cases diagnosed between 1999 and 2004 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10009/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hormone receptor (ER",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      PR) positive cancers comprised the majority of cases (n=48,851 cases, 80 percent).",
"     </li>",
"     <li>",
"      HER2 was overexpressed in 23 percent (n=13,921). Of these, 67 and 32 percent were hormone receptor-positive and negative, respectively.",
"     </li>",
"     <li>",
"      ER, PR, and HER2 negative (triple negative) cancers comprised 13 percent (n=8022).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the frequency of subtypes also varies according to race. As an example, in the Carolina Breast Cancer Study, compared to white women (n=631), African American women (n=518) were less likely to have hormone receptor",
"    <span class=\"nowrap\">",
"     (ER/PR)",
"    </span>",
"    positive, HER2-negative disease (48 versus 64 percent, respectively) and more likely to have",
"    <span class=\"nowrap\">",
"     ER/PR/HER2",
"    </span>",
"    negative disease (22 versus 11 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10009/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H340693972\">",
"    <span class=\"h2\">",
"     Role of imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women with newly diagnosed breast cancer, we reserve imaging for advanced or metastatic disease for the following indications:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with localized bone pain or an elevated alkaline phosphatase, we obtain a bone scan. If the bone scan is negative and clinical suspicion warrants further evaluation, an MRI should be performed localized to the symptomatic area.",
"     </li>",
"     <li>",
"      For patients with abnormal liver function tests, an elevated alkaline phosphatase, abdominal pain, or an abnormal abdominal or pelvic examination, we obtain a computed tomography (CT) of the abdomen. Abdominal MRI or ultrasound would be reasonable alternatives as would PET-CT.",
"     </li>",
"     <li>",
"      For patients presenting with pulmonary complaints (ie, cough or hemoptysis), we obtain a chest CT scan, although chest x-ray would be a reasonable alternative.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This approach is consistent with National Comprehensive Cancer Network guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10009/abstract/19\">",
"     19",
"    </a>",
"    ] and is based on multiple studies that have shown extensive imaging has little yield for most patients with newly diagnosed breast cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10009/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. In one of the largest reports, 516 consecutive patients seen at one institution for newly diagnosed breast cancer were retrospectively evaluated to determine the impact of staging [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10009/abstract/22\">",
"     22",
"    </a>",
"    ]. Major findings were:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A bone scan detected bony metastases in 26 of 412 patients (6 percent). The prevalence of a positive bone scan for women with pre-imaging stage I, II, and III breast cancer was 5, 6, and 14 percent, respectively.",
"     </li>",
"     <li>",
"      Liver ultrasound detected hepatic metastases in 3 of 412 patients (0.7 percent). No patients with stage I or II breast cancer had liver metastases. For patients with stage III breast cancer, the prevalence of a positive liver ultrasound was 6 percent.",
"     </li>",
"     <li>",
"      Chest x-ray detected lung metastases in 4 of 428 patients (0.9 percent). No patients with stage I or II breast cancer had pulmonary metastases. The prevalence of a positive chest X-ray among women with stage III disease was 7 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Positron emission testing (PET) scanning is not indicated in women with apparently early stage I or II breast cancer and those with operable stage III breast cancer. However, it is a reasonable test to perform to further work-up suspicious or equivocal findings on CT or MRI and for women with locally advanced disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast cancer is staged using the American Joint Committee on Cancer and the International Union for Cancer Control (AJCC-UICC) classification system for tumor, nodes, and metastases (TNM) (",
"    <a class=\"graphic graphic_table graphicRef65393 \" href=\"UTD.htm?29/14/29920\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10009/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the TNM system, patients are assigned a clinical stage (cTNM) preoperatively. Following surgery, the pathologic stage (pTNM) is then determined. For patients who undergo neoadjuvant treatment, the final pathologic stage is designated by the letter y (ypTNM). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24138?source=see_link\">",
"     \"Diagnostic evaluation of women with suspected breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/31/1529?source=see_link&amp;anchor=H441569430#H441569430\">",
"     \"Neoadjuvant systemic therapy for breast cancer: Response, subsequent treatment, and prognosis\", section on 'Pathologic assessment'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Primary tumor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical tumor (T) stage is assessed by clinical examination",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    imaging. While the majority of breast cancers are associated with abnormal mammographic findings, breast ultrasound (US)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    magnetic resonance imaging (MRI) may be required to accurately assess tumor size, particularly in patients presenting with a breast mass that is not identified on mammography. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24138?source=see_link&amp;anchor=H3#H3\">",
"     \"Diagnostic evaluation of women with suspected breast cancer\", section on 'Mammograms'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24138?source=see_link&amp;anchor=H10#H10\">",
"     \"Diagnostic evaluation of women with suspected breast cancer\", section on 'Ultrasonography'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24138?source=see_link&amp;anchor=H11#H11\">",
"     \"Diagnostic evaluation of women with suspected breast cancer\", section on 'Breast MRI'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Lymph nodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The status of the regional lymph nodes is one of the most important prognostic factors in early stage breast cancer. Physical examination is neither a sensitive nor reliable method to ascertain the status of the axillary lymph nodes because metastatic lymph nodes are often not palpable and reactive lymph nodes may be mistaken for metastases. The positive predictive value of clinical palpation ranges from 61 to 84 percent, while the negative predictive value is only 50 to 60 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10009/abstract/24-26\">",
"     24-26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given these findings, axillary staging should be performed. The assessment and management of the regional lymph nodes in breast cancer are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/52/42825?source=see_link\">",
"     \"Management of the regional lymph nodes in breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients presenting with breast cancer have disease confined to the breast (stage I to II) with no or limited (ie, less than three) nodes involved. For these patients, we do not routinely stage patients in the absence of signs or symptoms suspicious for metastatic disease. We restrict further work-up to patients who present with locally advanced (T3 or greater, N2 or N3, M0) (",
"    <a class=\"graphic graphic_table graphicRef65393 \" href=\"UTD.htm?29/14/29920\">",
"     table 1",
"    </a>",
"    ) or inflammatory breast cancer, and those with signs or symptoms suspicious for metastatic disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7354?source=see_link\">",
"     \"Systemic treatment for metastatic breast cancer: General principles\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/19/2357?source=see_link\">",
"       \"Patient information: Breast cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?11/56/12167?source=see_link\">",
"       \"Patient information: Breast cancer guide to diagnosis and treatment (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Breast cancer is the most common malignancy diagnosed worldwide. In the United States, the incidence of breast cancer declined between the 1990s and 2000s, likely due to the discontinuation of hormone replacement therapy (HRT) and the",
"      <span class=\"nowrap\">",
"       saturation/leveling",
"      </span>",
"      off of mammography rates. Of these factors, the discontinuation of HRT has probably had a greater effect. (See",
"      <a class=\"local\" href=\"#H365148828\">",
"       'Epidemiology and risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In countries with established breast cancer screening programs, approximately 50 percent of cancers are screen detected. Fifty percent present with clinical findings either because they are interval cancers (30 percent), mammographically occult (15 percent), or occur in women who are not undergoing screening (age, choice).",
"     </li>",
"     <li>",
"      Women with advanced cases of breast cancer may present with skin changes (also known as peau d&rsquo;orange) or axillary adenopathy. Less than five percent of patients present with signs or symptoms of metastatic breast cancer. (See",
"      <a class=\"local\" href=\"#H1749806644\">",
"       'Signs and symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women who present with abnormal imaging findings alone should undergo biopsy guided by mammogram (stereotactic biopsy), ultrasound, or breast MRI. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24504?source=see_link&amp;anchor=H3#H3\">",
"       \"Breast biopsy\", section on 'Stereotactic biopsy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24504?source=see_link&amp;anchor=H9#H9\">",
"       \"Breast biopsy\", section on 'Wire localization breast biopsy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24504?source=see_link&amp;anchor=H11#H11\">",
"       \"Breast biopsy\", section on 'MRI-guided breast biopsy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24504?source=see_link&amp;anchor=H4#H4\">",
"       \"Breast biopsy\", section on 'Core needle biopsy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Women presenting with a breast mass should undergo a fine needle aspiration or core needle biopsy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24504?source=see_link&amp;anchor=H2#H2\">",
"       \"Breast biopsy\", section on 'Fine needle aspiration biopsy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24504?source=see_link&amp;anchor=H4#H4\">",
"       \"Breast biopsy\", section on 'Core needle biopsy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In addition to a biopsy of the breast, women presenting with signs of inflammatory breast cancer (eg, rapidly progressing, tender, firm, and enlarged breast with thickening of the underlying skin) require two full thickness skin biopsies. The presence of dermal lymphatic invasion is pathognomonic for inflammatory breast cancer. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24504?source=see_link&amp;anchor=H12#H12\">",
"       \"Breast biopsy\", section on 'Skin punch biopsy'",
"      </a>",
"      .) Women with stage 2 and 3 breast cancers should be considered for neoadjuvant therapy.",
"     </li>",
"     <li>",
"      All women with newly diagnosed breast cancer should be told of any potential clinical trials in which they can participate (",
"      <a class=\"external\" href=\"file://breastcancertrials.org/\">",
"       breastcancertrials.org",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Women presenting with signs or symptoms of metastatic breast cancer should undergo a biopsy of the breast to confirm a diagnosis of primary breast cancer. In addition, biopsy of at least one metastatic lesion should also be performed to confirm the diagnosis of metastatic breast cancer.",
"     </li>",
"     <li>",
"      The diagnosis of breast cancer is defined by the presence of malignant epithelial cells (carcinoma) showing evidence of stromal invasion.",
"     </li>",
"     <li>",
"      The differential diagnosis of breast cancer varies based on how the patient presents. A separate differential diagnosis should be considered for patients who present with an abnormal mammogram or other imaging test or a breast mass. In addition, the pathologic findings on biopsy should also rule out other breast diagnoses. (See",
"      <a class=\"local\" href=\"#H1749806805\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most breast malignancies are carcinomas that arise from epithelial elements. However, there are various histologic types of breast carcinomas that differ in microscopic appearance and biologic behavior. Breast cancer can be categorized based on expression of estrogen (ER), progesterone (PR), and human epidermal growth factor (HER2) receptors. Each of these factors influence prognosis for patients with invasive breast cancer and is used to individualize treatment options. (See",
"      <a class=\"local\" href=\"#H1583246042\">",
"       'Pathology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1583246405\">",
"       'Post-diagnosis evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Gene expression studies allow for the molecular classification of breast cancer into distinct subtypes. These include luminal subtypes, which account for the majority of ER-positive breast cancers, a HER2 enriched subtype, and ER-negative or basal subtypes, which includes most triple-negative breast cancers. (See",
"      <a class=\"local\" href=\"#H1583246291\">",
"       'Molecular subtypes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Breast cancer is classified according to the American Joint Committee on Cancer and the International Union for Cancer Control (AJCC-UICC) for tumor, nodes, and metastases (TNM) (",
"      <a class=\"graphic graphic_table graphicRef65393 \" href=\"UTD.htm?29/14/29920\">",
"       table 1",
"      </a>",
"      ). In the TNM system, patients are assigned a clinical stage (cTNM) preoperatively. Following surgery, the pathologic stage (pTNM) can be assigned. For patients who undergo neoadjuvant treatment, the final pathologic stage is designated by the letter y (ypTNM). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Staging'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Globocan 2008. Fast Stats. Most frequent cancers: both sexes. file://globocan.iarc.fr/factsheets/populations/factsheet.asp?uno=900#BOTH (Accessed on January 08, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10009/abstract/2\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10009/abstract/3\">",
"      Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10009/abstract/4\">",
"      Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10009/abstract/5\">",
"      Kohler BA, Ward E, McCarthy BJ, et al. Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst 2011; 103:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10009/abstract/6\">",
"      Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 2007; 356:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10009/abstract/7\">",
"      Breen N, A Cronin K, Meissner HI, et al. Reported drop in mammography : is this cause for concern? Cancer 2007; 109:2405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10009/abstract/8\">",
"      Glass AG, Lacey JV Jr, Carreon JD, Hoover RN. Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst 2007; 99:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10009/abstract/9\">",
"      Robbins AS, Clarke CA. Regional changes in hormone therapy use and breast cancer incidence in California from 2001 to 2004. J Clin Oncol 2007; 25:3437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10009/abstract/10\">",
"      Chlebowski RT, Kuller LH, Prentice RL, et al. Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 2009; 360:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10009/abstract/11\">",
"      Marshall SF, Clarke CA, Deapen D, et al. Recent breast cancer incidence trends according to hormone therapy use: the California Teachers Study cohort. Breast Cancer Res 2010; 12:R4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10009/abstract/12\">",
"      Esserman LJ, Shieh Y, Rutgers EJ, et al. Impact of mammographic screening on the detection of good and poor prognosis breast cancers. Breast Cancer Res Treat 2011; 130:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10009/abstract/13\">",
"      Stavros AT, Thickman D, Rapp CL, et al. Solid breast nodules: use of sonography to distinguish between benign and malignant lesions. Radiology 1995; 196:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10009/abstract/14\">",
"      Macura KJ, Ouwerkerk R, Jacobs MA, Bluemke DA. Patterns of enhancement on breast MR images: interpretation and imaging pitfalls. Radiographics 2006; 26:1719.",
"     </a>",
"    </li>",
"    <li>",
"     Dizon DS, Tejada-Berges T, Steinhoff MM, et al.. Breast Cancer. In: Principles and Practice of Gynecologic Oncology, 5, RR Barakat, M Markman, ME Randall.  (Eds), Lippincott, Williams, &amp; Wilkins, Baltimore 2009. p.910.",
"    </li>",
"    <li>",
"     Breast Imaging Reporting and Data System: ACR BI-RADS &ndash; Breast Imaging Atlas, D'Orsi CJ, Mendelson EB, Ikeda DM, et al.  (Eds), American College of Radiology, Reston, VA 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10009/abstract/17\">",
"      Parise CA, Bauer KR, Brown MM, Caggiano V. Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004. Breast J 2009; 15:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10009/abstract/18\">",
"      O'Brien KM, Cole SR, Tse CK, et al. Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin Cancer Res 2010; 16:6100.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10009/abstract/20\">",
"      Myers RE, Johnston M, Pritchard K, et al. Baseline staging tests in primary breast cancer: a practice guideline. CMAJ 2001; 164:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10009/abstract/21\">",
"      Puglisi F, Follador A, Minisini AM, et al. Baseline staging tests after a new diagnosis of breast cancer: further evidence of their limited indications. Ann Oncol 2005; 16:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10009/abstract/22\">",
"      Ravaioli A, Pasini G, Polselli A, et al. Staging of breast cancer: new recommended standard procedure. Breast Cancer Res Treat 2002; 72:53.",
"     </a>",
"    </li>",
"    <li>",
"     American Joint Committee on Cancer Staging Manual, 7th, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10009/abstract/24\">",
"      de Freitas R Jr, Costa MV, Schneider SV, et al. Accuracy of ultrasound and clinical examination in the diagnosis of axillary lymph node metastases in breast cancer. Eur J Surg Oncol 1991; 17:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10009/abstract/25\">",
"      Lanng C, Hoffmann J, Galatius H, Engel U. Assessment of clinical palpation of the axilla as a criterion for performing the sentinel node procedure in breast cancer. Eur J Surg Oncol 2007; 33:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10009/abstract/26\">",
"      Vaidya JS, Vyas JJ, Thakur MH, et al. Role of ultrasonography to detect axillary node involvement in operable breast cancer. Eur J Surg Oncol 1996; 22:140.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 744 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.167.4.114-B39C775BF0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_49_10009=[""].join("\n");
var outline_f9_49_10009=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H365148828\">",
"      EPIDEMIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1749806335\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1583245923\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1749806644\">",
"      Signs and symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H373972748\">",
"      - Breast mass",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H373972809\">",
"      - Locally advanced disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H373972816\">",
"      - Metastatic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1583246595\">",
"      Imaging findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1583246042\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1583246092\">",
"      - Infiltrating ductal carcinoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1583246099\">",
"      - Infiltrating lobular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1583246106\">",
"      - Mixed ductal/lobular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1583246291\">",
"      Molecular subtypes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1583246318\">",
"      - Luminal subtypes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1583246325\">",
"      - HER2-enriched",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1583246332\">",
"      - Basal subtypes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1749806798\">",
"      EVALUATION OF SUSPECTED DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28333270\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1749806805\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H373972913\">",
"      Breast mass",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1583247104\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H373972920\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1583246405\">",
"      POST-DIAGNOSIS EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1662781741\">",
"      Breast cancer receptor testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H856570592\">",
"      - ER and PR",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H856570599\">",
"      - HER2",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H856570606\">",
"      - Frequency of subtypes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H340693972\">",
"      Role of imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      STAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Primary tumor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Lymph nodes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/744\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/744|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?28/38/29295\" title=\"diagnostic image 1\">",
"      Abnormal mammogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?15/24/15748\" title=\"diagnostic image 2\">",
"      Ultrasound of early breast cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?0/34/549\" title=\"diagnostic image 3\">",
"      MRI breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/744|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/14/29920\" title=\"table 1\">",
"      TNM stage breast cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/14/44265?source=related_link\">",
"      Atypia and lobular carcinoma in situ: High risk lesions of the breast",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24504?source=related_link\">",
"      Breast biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/51/17207?source=related_link\">",
"      Breast cancer during pregnancy and lactation: Epidemiology and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/36/26186?source=related_link\">",
"      Breast cancer in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/60/4040?source=related_link\">",
"      Breast cysts: Clinical manifestations, diagnosis, and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/33/6680?source=related_link\">",
"      Breast ductal carcinoma in situ: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39482?source=related_link\">",
"      Breast imaging: Mammography and ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/19/36150?source=related_link\">",
"      Breast lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24825?source=related_link\">",
"      Breast masses and other common breast problems",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/3/28729?source=related_link\">",
"      Breast sarcoma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/36/24138?source=related_link\">",
"      Diagnostic evaluation of women with suspected breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/43/37561?source=related_link\">",
"      Ductal carcinoma in situ: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/40/34441?source=related_link\">",
"      Epidemiology, risk factors and the clinical approach to ER/PR negative, HER2-negative (Triple-negative) breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28954?source=related_link\">",
"      Factors that modify breast cancer risk in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/22/30058?source=related_link\">",
"      HER2 and predicting response to therapy in breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19194?source=related_link\">",
"      Hormone receptors in breast cancer: Clinical utility and guideline recommendations to improve test accuracy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/20/31048?source=related_link\">",
"      Inflammatory breast cancer: Clinical features and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/29/23002?source=related_link\">",
"      MRI of the breast and emerging technologies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/52/42825?source=related_link\">",
"      Management of the regional lymph nodes in breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/28/43465?source=related_link\">",
"      Measurement of prognostic factors in breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/41/14998?source=related_link\">",
"      Microinvasive breast carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/21/41302?source=related_link\">",
"      Molecular intrinsic subtypes of breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/31/1529?source=related_link\">",
"      Neoadjuvant systemic therapy for breast cancer: Response, subsequent treatment, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11081?source=related_link\">",
"      Overview of benign breast disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/46/19177?source=related_link\">",
"      Overview of the treatment of newly diagnosed, non-metastatic breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/0/14?source=related_link\">",
"      Paget disease of the breast",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/42/16040?source=related_link\">",
"      Pathology of breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/19/2357?source=related_link\">",
"      Patient information: Breast cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/56/12167?source=related_link\">",
"      Patient information: Breast cancer guide to diagnosis and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/0/8202?source=related_link\">",
"      Patterns of relapse and long-term complications of therapy in breast cancer survivors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/23/32122?source=related_link\">",
"      Postmenopausal hormone therapy: Benefits and risks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41754?source=related_link\">",
"      Screening for breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7354?source=related_link\">",
"      Systemic treatment for metastatic breast cancer: General principles",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_49_10010="Congenital rubella syndrome: Clinical features and diagnosis";
var content_f9_49_10010=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Congenital rubella syndrome: Clinical features and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/49/10010/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/49/10010/contributors\">",
"     Simon R Dobson, MD, FRCP(C)",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/49/10010/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/49/10010/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/49/10010/contributors\">",
"     Leonard E Weisman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/49/10010/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/49/10010/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/49/10010/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 7, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features and diagnosis of congenital rubella infection will be reviewed here. The epidemiology of rubella infection, risk of rubella-associated congenital defects, and management of congenital rubella infection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/14/26855?source=see_link\">",
"     \"Rubella\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/60/6087?source=see_link\">",
"     \"Rubella in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36855?source=see_link\">",
"     \"Congenital rubella syndrome: Management, outcome, and prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Congenital rubella infection &ndash; Congenital rubella infection (CRI) encompasses all outcomes associated with intrauterine rubella infection (eg, miscarriage, stillbirth, combinations of birth defects, asymptomatic infection) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Congenital rubella syndrome &ndash; Congenital rubella syndrome (CRS) refers to variable constellations of birth defects (eg, hearing impairment, congenital heart defects,",
"      <span class=\"nowrap\">",
"       cataracts/congenital",
"      </span>",
"      glaucoma, pigmentary retinopathy, etc.) (",
"      <a class=\"graphic graphic_table graphicRef55913 \" href=\"UTD.htm?38/56/39820\">",
"       table 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epidemiology of rubella infection is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/60/6087?source=see_link&amp;anchor=H2#H2\">",
"     \"Rubella in pregnancy\", section on 'Epidemiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/14/26855?source=see_link&amp;anchor=H3#H3\">",
"     \"Rubella\", section on 'Epidemiology and vaccine development'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Congenital rubella syndrome (CRS) is rare in developed countries with established rubella immunization programs [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. It is no longer endemic in the United States, although an average of five to six cases are reported to the National Congenital Rubella Syndrome Registry each year (",
"    <a class=\"graphic graphic_figure graphicRef70446 \" href=\"UTD.htm?17/22/17775\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/2,5,6\">",
"     2,5,6",
"    </a>",
"    ]. These cases typically occur in infants whose mothers emigrated from countries without rubella immunization programs.",
"   </p>",
"   <p>",
"    In much of the developing world, rubella is uncontrolled, and there is a high burden of disease for CRS (ranging between approximately 10 and 90 per 100,000 live births) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/7-14\">",
"     7-14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal-fetal transmission of rubella virus occurs via hematogenous spread during maternal viremia, which usually occurs five to seven days after maternal inoculation. After infecting the placenta, the virus spreads through the vascular system of the developing fetus. The resulting congenital defects stem from cytopathic damage to blood vessels and ischemia in affected organs [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/15-18\">",
"     15-18",
"    </a>",
"    ]. Fetal infection is chronic, persisting throughout gestation and after birth.",
"   </p>",
"   <p>",
"    The risk of maternal-fetal transmission varies depending upon the time of maternal infection, with the highest risk in the first 10 weeks of gestation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/60/6087?source=see_link&amp;anchor=H6#H6\">",
"     \"Rubella in pregnancy\", section on 'Congenital rubella syndrome'",
"    </a>",
"    .) The clinical manifestations also vary depending upon the time of maternal infection. Structural cardiac and eye defects typically result when maternal infection occurs before eight weeks, whereas hearing loss may be observed in maternal infections until 18 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Congenital defects are unlikely if maternal infection occurs after 18 to 20 weeks' gestation.",
"   </p>",
"   <p>",
"    There are two proposed mechanisms for rubella cytopathology: virus-induced inhibition of cell division and direct cytopathic effects. Support for virus-induced inhibition of cell division is provided by observations that organs of congenitally infected infants are smaller and contain fewer cells than those of uninfected infants [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/21\">",
"     21",
"    </a>",
"    ] ; mitotic activity is depressed in congenitally infected embryonic primary cell cultures [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/17\">",
"     17",
"    </a>",
"    ]; cell division is slowed in human fetal cells and BHK-21 cells that have been infected with rubella virus in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]; and a protein extracted from rubella-virus-infected human fetal cells inhibits mitosis in uninfected cells [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Support for direct cytopathic effects is provided by an in vitro study demonstrating variable degrees of rubella-virus-induced programmed cell death (apoptosis) in different cell lines [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/26\">",
"     26",
"    </a>",
"    ]. These findings suggest that programmed cell death depends upon unique cellular properties and may provide an explanation for selective organ damage in congenital rubella syndrome. Subsequent studies demonstrating cell-specific rubella-virus-induced apoptosis (in chorionic villi explants, monolayers of cytotrophoblasts, and adult lung fibroblasts, but not in primary human fetal fibroblasts) may help to explain the persistence of virus in congenital rubella syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Other possible explanations for the persistence of rubella virus in congenital rubella syndrome include defects in cell-mediated immunity and selective immune tolerance to the rubella virus E1 protein [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/29-31\">",
"     29-31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     IMMUNOLOGIC RESPONSE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Humoral response",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the first one-half of gestation, only 5 to 10 percent of maternal IgG rubella antibody is passively transferred to the fetus. The fetus's own immunoglobulin M (IgM), immunoglobulin G (IgG), and immunoglobulin A (IgA) appear at 9 to 11 weeks of gestation, but circulating fetal antibody levels remain low. Fetal antibody levels increase at mid-gestation, with predominance of IgM. At the time of delivery, IgG predominates and is mainly of maternal origin; IgM levels are lower but entirely of fetal origin [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At three to five months of age, maternally derived IgG decreases and infant IgM increases. In children with congenital rubella infection, rubella-specific IgM generally persists for at least six months, often persists for up to one year, and occasionally persists for up to two years [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/33\">",
"     33",
"    </a>",
"    ]. High levels of infant rubella-specific IgG antibody usually are sustained for several years after detectable rubella virus excretion ends. Over time, rubella-specific antibody levels decrease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/33\">",
"     33",
"    </a>",
"    ]; in 10 to 20 percent of patients, they may become undetectable [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/34-37\">",
"     34-37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some patients with congenital rubella infection have a relative hypergammaglobulinemia (particularly of IgM and IgG) during the first few years of life, which results from the increased antigenic stimulus accompanying the chronic infection [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/38\">",
"     38",
"    </a>",
"    ]. There are a few case reports of hypogammaglobulinemia following intrauterine rubella infection, which usually affects only IgA, but may involve IgG, IgM, and IgA [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Alternatively, IgG may be decreased and IgM increased (two to three times normal adult levels) with or without abnormalities in IgA [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40076903\">",
"    <span class=\"h3\">",
"     Lack of booster response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with congenital rubella infection who have lost detectable rubella-specific antibody do not develop a boost in antibody titer after rubella vaccination [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/35,40\">",
"     35,40",
"    </a>",
"    ]. This may reflect immunologic tolerance following intrauterine exposure to rubella virus. The mechanism of immune tolerance is not known but may be related to selective tolerance to the rubella virus E1 protein or the immaturity of the fetal immune system during the first trimester of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/31,41\">",
"     31,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Cellular response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Defects in cell-mediated immunity and persistent T cell abnormalities have been reported in patients with congenital rubella infection, particularly when infection occurs early in gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/30,42-45\">",
"     30,42-45",
"    </a>",
"    ]. Delayed type hypersensitivity reactions, lymphocyte mediated cytotoxicity, phytohemagglutinin-induced lymphocyte transformation, and interferon production are decreased compared with responses in individuals with postnatal rubella infection. T cell abnormalities may predispose patients with congenital rubella infection to develop organ-specific autoimmunity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40076910\">",
"    <span class=\"h3\">",
"     Possible role in autoimmunity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital rubella infection is associated with increased risk for diabetes and thyroid disease. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Late manifestations'",
"    </a>",
"    below.) Patients with congenital rubella infection have a high prevalence of pancreatic islet cell surface antibodies and antithyroid antibodies, suggesting that immune-mediated mechanisms may play a role in the development of diabetes and thyroid disease. However, there is no clear evidence that congenital rubella predisposes to subsequent autoimmunity. Approximately 20 percent of patients with congenital rubella syndrome have pancreatic islet cell surface antibodies, but pancreatic islet cell antibodies (which are more closely related to immune-mediated diabetes) have not been detected [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. This suggests that other factors, such as HLA type, are also important in the development of type 1 diabetes in patients with congenital rubella infection [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/46,47,49-52\">",
"     46,47,49-52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23210?source=see_link\">",
"     \"Pathogenesis of type 1 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital rubella infection (CRI) may lead to fetal death in utero, premature delivery, or congenital defects [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/1\">",
"     1",
"    </a>",
"    ]. CRI is a chronic infection and has a broad spectrum of clinical manifestations that may manifest throughout life (",
"    <a class=\"graphic graphic_table graphicRef75721 \" href=\"UTD.htm?15/35/15933\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/1,53\">",
"     1,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Deafness, cataracts (",
"    <a class=\"graphic graphic_picture graphicRef64979 \" href=\"UTD.htm?37/11/38079\">",
"     picture 1",
"    </a>",
"    ), and cardiac disease are the classic manifestations of congenital rubella syndrome (CRS) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. However, rubella virus may infect virtually every fetal organ [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/38\">",
"     38",
"    </a>",
"    ]. Once CRI is established, it can persist for long periods. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Viral shedding'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The manifestations of CRI vary depending upon the timing of maternal infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/60/6087?source=see_link&amp;anchor=H6#H6\">",
"     \"Rubella in pregnancy\", section on 'Congenital rubella syndrome'",
"    </a>",
"    .) The incidence of defects may be as high as 80 to 85 percent if maternal rubella is acquired during the first trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/19,34,56\">",
"     19,34,56",
"    </a>",
"    ]. Little, if any, risk of congenital defects is associated with infection after 18 to 20 weeks' gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/19,57\">",
"     19,57",
"    </a>",
"    ]; intrauterine growth retardation may be the only sequela of third-trimester infection [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/34,58-60\">",
"     34,58-60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The majority of infants with CRI are asymptomatic at birth but develop manifestations over time (",
"    <a class=\"graphic graphic_table graphicRef75721 \" href=\"UTD.htm?15/35/15933\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/61-64\">",
"     61-64",
"    </a>",
"    ]. In prospective surveillance of 4005 infants born after the 1964 rubella epidemic in the United States, 68 percent of infected newborns had subclinical infection during the neonatal period [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/61\">",
"     61",
"    </a>",
"    ]. However, 71 percent of those who were followed developed clinical manifestations in the first five years of life. The lack of clinical manifestations during the newborn period and the risk for progression highlight the importance of timely diagnosis and appropriate short- and long-term management [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36855?source=see_link\">",
"     \"Congenital rubella syndrome: Management, outcome, and prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     In neonates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Manifestations of congenital rubella infection (CRI) during the neonatal period may include (",
"    <a class=\"graphic graphic_table graphicRef75721 \" href=\"UTD.htm?15/35/15933\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/20,29,56,65\">",
"     20,29,56,65",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Intrauterine growth retardation",
"     </li>",
"     <li>",
"      Meningoencephalitis, large anterior fontanelle",
"     </li>",
"     <li>",
"      Hearing loss",
"     </li>",
"     <li>",
"      Cloudy cornea, cataract (",
"      <a class=\"graphic graphic_picture graphicRef64979 \" href=\"UTD.htm?37/11/38079\">",
"       picture 1",
"      </a>",
"      ), infantile glaucoma, retinopathy (",
"      <a class=\"graphic graphic_picture graphicRef70003 \" href=\"UTD.htm?6/51/6967\">",
"       picture 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Interstitial pneumonia (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/0/21512?source=see_link\">",
"       \"Neonatal pneumonia\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cardiac defects",
"     </li>",
"     <li>",
"      Hepatosplenomegaly, jaundice, hepatitis, diarrhea",
"     </li>",
"     <li>",
"      Radiolucent bone lesions (in the long bones)",
"     </li>",
"     <li>",
"      Petechiae and purpura (\"blueberry muffin lesions\") (",
"      <a class=\"graphic graphic_picture graphicRef69581 \" href=\"UTD.htm?33/32/34305\">",
"       picture 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Adenopathy",
"     </li>",
"     <li>",
"      Hemolytic anemia, thrombocytopenia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many of these manifestations are transient and not necessarily specific for CRI [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/38\">",
"     38",
"    </a>",
"    ] . They typically clear spontaneously over days or weeks. However, they may have important diagnostic and prognostic implications. The risk of mortality is increased in neonates with severe defects (eg, extreme prematurity, extensive meningoencephalitis, gross cardiac lesions or myocarditis with early heart failure, fulminant interstitial pneumonitis, and rapidly progressive hepatitis) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     In infants and children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Structural defects in infants and children with congenital rubella syndrome (CRS) include hearing loss, cardiac and vascular anomalies, eye lesions, and central nervous system abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/38\">",
"     38",
"    </a>",
"    ]. These generally result from defective organogenesis or scarring. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Pathogenesis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Nearly two-thirds of children with intrauterine rubella infection have long-term deafness, which is usually bilateral and sensorineural [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44344?source=see_link\">",
"     \"Evaluation of hearing impairment in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approximately one-half of children infected during the first two months of gestation have congenital heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/1\">",
"     1",
"    </a>",
"    ]. Patent ductus arteriosus and branch pulmonary artery stenosis are the most common lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/66\">",
"     66",
"    </a>",
"    ]. Other lesions, including pulmonary valvular stenosis, aortic valve stenosis, ventricular septal defect, tetralogy of Fallot, and coarctation of the aorta, have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/53,66\">",
"     53,66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/52/35656?source=see_link\">",
"     \"Clinical manifestations and diagnosis of patent ductus arteriosus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38345?source=see_link\">",
"     \"Valvar aortic stenosis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/27/13752?source=see_link\">",
"     \"Pathophysiology, clinical features, and diagnosis of tetralogy of Fallot\"",
"    </a>",
"    .) Stenosis of other vessels may be related to coronary, cerebral, renal, and peripheral vascular disease during adulthood [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/67,68\">",
"     67,68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cataracts occur in about one-quarter of infants with CRS; infantile glaucoma is less frequent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/1\">",
"     1",
"    </a>",
"    ]. Cataracts and infantile glaucoma usually become apparent during the early weeks of life. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22761?source=see_link\">",
"     \"Cataract in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/31/41463?source=see_link&amp;anchor=H9#H9\">",
"     \"Overview of glaucoma in infants and children\", section on 'Secondary glaucoma'",
"    </a>",
"    .) \"Salt and pepper\" retinopathy (",
"    <a class=\"graphic graphic_picture graphicRef70003 \" href=\"UTD.htm?6/51/6967\">",
"     picture 2",
"    </a>",
"    ) is caused by disturbed growth of the pigmentary layer of the retina [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/20,38\">",
"     20,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Central nervous system abnormalities may include microcephaly (27 percent) and intellectual disability (formerly mental retardation; in 13 percent). Motor delay, behavioral disorders, autism, and psychiatric disorders are less common [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/20,38\">",
"     20,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Late manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delayed manifestations of congenital rubella infection (CRI) occur in at least 20 percent of children with symptomatic congenital rubella infection [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/67\">",
"     67",
"    </a>",
"    ]. Some of the late manifestations may relate to subtle damage that is present but not detected in early life. Late manifestations include [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/67\">",
"     67",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hearing loss",
"     </li>",
"     <li>",
"      Endocrine disorders",
"     </li>",
"     <li>",
"      Eye problems",
"     </li>",
"     <li>",
"      Vascular effects",
"     </li>",
"     <li>",
"      Progressive panencephalitis",
"     </li>",
"     <li>",
"      Immune defects",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28489670\">",
"    <span class=\"h3\">",
"     Hearing loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Permanent hearing loss is the most common late manifestation of CRI, ultimately occurring in up to 80 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/38\">",
"     38",
"    </a>",
"    ]. Hearing loss is usually sensorineural and bilateral. It ranges in severity from mild to profound and may progress over time. Rarely, sudden onset of hearing loss may occur after years of normal hearing [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/69,70\">",
"     69,70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28489677\">",
"    <span class=\"h3\">",
"     Endocrine disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Late manifestations of intrauterine rubella infection may include diabetes, thyroid disease, and growth hormone deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Long-term follow-up of patients with congenital rubella syndrome (CRS) following the 1941 rubella epidemic in Australia indicated that 20 percent (9 of 44) had overt or latent diabetes by the age of 25 years and 22 percent had type 2 diabetes by age 50 to 60 years (compared with a background prevalence of 13 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/62,71\">",
"     62,71",
"    </a>",
"    ]. More recent case series suggest that approximately 1 percent of individuals with congenital rubella infection develop diabetes in childhood and adolescence [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/48,72-74\">",
"     48,72-74",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23210?source=see_link&amp;anchor=H17#H17\">",
"     \"Pathogenesis of type 1 diabetes mellitus\", section on 'Role of viruses'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thyroid dysfunction affects about 5 percent of patients with CRS. It manifests as hyperthyroidism, hypothyroidism, and thyroiditis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/75-79\">",
"     75-79",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/29/7641?source=see_link\">",
"     \"Clinical manifestations and diagnosis of hyperthyroidism in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21865?source=see_link\">",
"     \"Acquired hypothyroidism in childhood and adolescence\"",
"    </a>",
"    .) A high prevalence of thyroid microsomal or thyroglobulin antibodies has been observed in patients with CRS, suggesting that immune-mediated mechanisms may play a role, but there is no clear evidence that congenital rubella predisposes to autoimmunity. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Humoral response'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    CRS may occasionally be related to growth hormone deficiency and short stature [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/80\">",
"     80",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/5/82?source=see_link\">",
"     \"Diagnosis of growth hormone deficiency in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28489684\">",
"    <span class=\"h3\">",
"     Eye problems",
"    </span>",
"    &nbsp;&mdash;&nbsp;Late-onset ophthalmologic manifestations of CRS may include pigmentary retinopathy (",
"    <a class=\"graphic graphic_picture graphicRef70003 \" href=\"UTD.htm?6/51/6967\">",
"     picture 2",
"    </a>",
"    ) (in approximately 40 to 60 percent of cases), cataracts, glaucoma (in 2 to 15 percent of cases), keratic precipitates, keratoconus, corneal hydrops, microphthalmos (estimated to occur in 10 to 20 percent of cases), strabismus, and absorption of the cataractous lens [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/67,81,82\">",
"     67,81,82",
"    </a>",
"    ]. This damage can appear years or even decades after birth [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28489691\">",
"    <span class=\"h3\">",
"     Vascular effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vascular sequelae of CRS may include fibromuscular proliferation of the intima, sclerosis of arteries, systemic hypertension secondary to renal disease, and subretinal neovascularization [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. These lesions are potential causes of coronary, cerebral, and peripheral vascular disease in adulthood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28489698\">",
"    <span class=\"h3\">",
"     Panencephalitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progressive rubella panencephalitis most commonly occurs in the second decade of life [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. It is slowly progressive and fatal. The initial findings are usually learning problems and ataxia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28489705\">",
"    <span class=\"h3\">",
"     Immune defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Defects in specific antibody production, repeated infections, and defective T-cell response with associated autoimmune phenomena have been observed in patients with CRS [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/85,86\">",
"     85,86",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Viral shedding",
"    </span>",
"    &nbsp;&mdash;&nbsp;After fetal infection, rubella virus persists throughout gestation and for months postnatally. It can be recovered from multiple sites.",
"   </p>",
"   <p>",
"    Pharyngeal shedding of rubella virus is common, prolonged, and intense during the months after delivery. At one year of age, as many as 20 percent of infants with congenital rubella syndrome (CRS) continue to shed rubella virus in the pharynx, but by two years of age, pharyngeal shedding is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/56,87-91\">",
"     56,87-91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with ocular and central nervous system involvement (eg, cataracts, late subacute panencephalitis), rubella virus has been cultured from the crystalline lens and cerebrospinal fluid in children older than one year of age [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/84,87,92,93\">",
"     84,87,92,93",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H263857150\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital rubella must be differentiated from other intrauterine infections (",
"    <a class=\"graphic graphic_table graphicRef76743 \" href=\"UTD.htm?32/26/33196\">",
"     table 3",
"    </a>",
"    ) and other conditions that have similar manifestations in the newborn, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Congenital toxoplasmosis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/12/43208?source=see_link&amp;anchor=H11762879#H11762879\">",
"       \"Congenital toxoplasmosis: Clinical features and diagnosis\", section on 'Evaluation and diagnosis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Congenital cytomegalovirus (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28041?source=see_link&amp;anchor=H29#H29\">",
"       \"Overview of TORCH infections\", section on 'Congenital cytomegalovirus'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Congenital herpes simplex virus (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/31/35321?source=see_link&amp;anchor=H11#H11\">",
"       \"Neonatal herpes simplex virus infection: Clinical features and diagnosis\", section on 'Evaluation and diagnosis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Congenital syphilis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/31/17914?source=see_link&amp;anchor=H28809398#H28809398\">",
"       \"Congenital syphilis: Clinical features and diagnosis\", section on 'Approach to diagnosis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Other conditions that cause sensorineural hearing loss (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/38/19050?source=see_link&amp;anchor=H16#H16\">",
"       \"Etiology of hearing impairment in children\", section on 'Congenital'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Other conditions that cause corneal clouding, including infantile glaucoma (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/57/5016?source=see_link&amp;anchor=H13#H13\">",
"       \"Primary infantile glaucoma\", section on 'Corneal clouding'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Congenital heart disease (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33482?source=see_link\">",
"       \"Congenital heart disease (CHD) in the newborn: Presentation and screening for critical CHD\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     EVALUATION AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Timely diagnosis of congenital rubella infection (CRI) is necessary for proper management [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/38\">",
"     38",
"    </a>",
"    ]. Although the diagnosis may be suspected clinically, it is confirmed with laboratory tests (",
"    <a class=\"graphic graphic_table graphicRef55913 \" href=\"UTD.htm?38/56/39820\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Clinical suspicion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possibility of congenital rubella infection (CRI) should be considered in [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/1,94\">",
"     1,94",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Any infant born to a woman who had documented or suspected rubella infection at any time during pregnancy; treatment of maternal rubella infection with immunoglobulin does not guarantee protection from fetal infection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/60/6087?source=see_link&amp;anchor=H9#H9\">",
"       \"Rubella in pregnancy\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Any infant with intrauterine growth retardation or other clinical manifestations of congenital rubella syndrome (CRS) (",
"      <a class=\"graphic graphic_table graphicRef55913 \" href=\"UTD.htm?38/56/39820\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef75721 \" href=\"UTD.htm?15/35/15933\">",
"       table 2",
"      </a>",
"      ) regardless of maternal history (subclinical maternal rubella infection may cause congenital malformations).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, newborns who fail hearing screening should undergo evaluation for rubella (measurement of rubella-specific IgM antibodies) and other intrauterine infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44344?source=see_link\">",
"     \"Evaluation of hearing impairment in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of certain defects or laboratory data consistent with CRS satisfies the Centers for Disease Control and Prevention's clinical case definition (",
"    <a class=\"graphic graphic_table graphicRef55913 \" href=\"UTD.htm?38/56/39820\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/95\">",
"     95",
"    </a>",
"    ]. Cases of CRS are classified as \"suspected\", \"probable\", \"confirmed\", or \"infection only\", depending upon clinical findings and laboratory criteria for diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation of a newborn with clinical findings compatible with intrauterine rubella infection (eg, cataract, congenital cardiac defect) is the same as the evaluation for other intrauterine infections. It should include [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/1,32\">",
"     1,32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Review of maternal history (evidence of rubella immunity)",
"     </li>",
"     <li>",
"      Assessment of physical stigmata consistent with the syndrome (",
"      <a class=\"graphic graphic_table graphicRef55913 \" href=\"UTD.htm?38/56/39820\">",
"       table 1",
"      </a>",
"      ), including complete cardiac and neurologic examinations (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical features'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Complete blood count and platelet count",
"     </li>",
"     <li>",
"      Liver function tests",
"     </li>",
"     <li>",
"      Radiographs of long bones",
"     </li>",
"     <li>",
"      Ophthalmologic evaluation",
"     </li>",
"     <li>",
"      Audiologic evaluation",
"     </li>",
"     <li>",
"      Neuroimaging (eg, ultrasonography, computed tomography) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/96\">",
"       96",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Lumbar puncture",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some experts suggest echocardiography for all infants in whom congenital rubella syndrome is suspected, whereas others suggest cardiology consultation and echocardiography based upon clinical examination findings [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/1,66\">",
"     1,66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33482?source=see_link\">",
"     \"Congenital heart disease (CHD) in the newborn: Presentation and screening for critical CHD\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Laboratory diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the diagnosis of congenital rubella syndrome (CRS) may be suspected clinically, it is confirmed with laboratory tests (",
"    <a class=\"graphic graphic_table graphicRef55913 \" href=\"UTD.htm?38/56/39820\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Laboratory evaluation should be performed before the child reaches one year of age, after which it is difficult to establish a diagnosis of congenital rubella infection [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/97\">",
"     97",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Retrospective diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Laboratory confirmation of congenital rubella infection (CRI) can be established through isolation of rubella virus, demonstration of rubella-specific IgM antibodies, demonstration of rubella-specific IgG antibodies that persist at a higher concentration or longer duration than expected from passive transfer of maternal antibody, or detection of rubella virus RNA (",
"    <a class=\"graphic graphic_table graphicRef55913 \" href=\"UTD.htm?38/56/39820\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cost, length of time required for definitive results, and expertise required for performance of these tests vary. Demonstration of rubella-specific IgM antibodies with commercially available enzyme immunoassay kits is the preferred initial test, particularly for infants in the first two months of life [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/1,98\">",
"     1,98",
"    </a>",
"    ]. Measurement of rubella-specific IgG is most helpful in infants between 6 and 12 months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/1,56\">",
"     1,56",
"    </a>",
"    ]. Consultation with an expert in pediatric infectious diseases is suggested if there are questions regarding the appropriate diagnostic strategy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Virus isolation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of CRI can be confirmed by the isolation of the rubella virus [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/1\">",
"     1",
"    </a>",
"    ]. Rubella virus is most frequently isolated from nasopharyngeal secretions, although it can also be cultured from blood (including cord blood), placenta, urine, and cerebrospinal fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/38,94\">",
"     38,94",
"    </a>",
"    ]. Specialized testing is necessary for rubella virus, so laboratory personnel should be notified that rubella virus is suspected [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Virus isolation should be attempted as soon as congenital rubella is suspected, because viral excretion wanes during infancy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/38\">",
"     38",
"    </a>",
"    ]. Isolation of rubella virus may be possible for several years from lens tissue in children with cataracts or cerebrospinal fluid in children with encephalitis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/84,92\">",
"     84,92",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Serology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serologic confirmation of CRS consists of demonstration of rubella-specific IgM antibody or infant IgG rubella antibody level that persists at a higher level and for a longer time than expected from passive transfer of maternal antibody [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/94,95\">",
"     94,95",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Humoral response'",
"    </a>",
"    above.) Serologic testing is more likely to be available in developing countries [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Detection of rubella-specific IgM antibody in the neonatal serum or cord blood provides laboratory evidence of recent postnatal or congenital rubella infection in the newborn [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/29,38,94\">",
"     29,38,94",
"    </a>",
"    ]. IgM testing is most helpful in infants younger than two months, although IgM may be detectable for as long as 12 months in some infants [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/1\">",
"     1",
"    </a>",
"    ]. Infants with symptoms consistent with CRS who test negative soon after birth should be retested at age one month because approximately 20 percent of infected infants tested for rubella IgM may not have detectable titers before age one month [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/94\">",
"     94",
"    </a>",
"    ]. In infants older than two months, positive IgM is helpful, but negative IgM does not exclude infection. False-positive IgM results may be caused by rheumatoid factor, parvovirus, and heterophile antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Monitoring rubella-specific IgG over time (eg, at 3, 6, and, if necessary, 12 months of age) also may confirm congenital or recent postnatal rubella infection if rubella-specific IgG persists at a higher level and for a longer time would be expected for maternal IgG [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/94,95\">",
"     94,95",
"    </a>",
"    ]. Maternal rubella antibody has a half-life of approximately 30 days; it should decrease by four- to eightfold by three months of age and should disappear by 6 to 12 months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/32,38,94\">",
"     32,38,94",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Humoral response'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Monitoring rubella-specific IgG is less desirable than the other methods of laboratory diagnosis because it may delay diagnosis, does not necessarily distinguish congenital from postnatal infection, and does not absolutely exclude intrauterine infection (if the infant has low antibody levels because of agammaglobulinemia or dysgammaglobulinemia) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/32,94\">",
"     32,94",
"    </a>",
"    ]. In questionable cases, assessment of IgG rubella antibody avidity may be helpful [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/99,100\">",
"     99,100",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Retrospective diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Rubella virus PCR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Detection of rubella virus RNA by polymerase chain reaction (PCR) also provides laboratory evidence of CRI [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/94,95,97\">",
"     94,95,97",
"    </a>",
"    ] but may not be available in all settings [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/1\">",
"     1",
"    </a>",
"    ]. PCR may be performed on throat swabs, respiratory secretions, CNS tissues and CSF, amniotic fluid, and products of conception, urine samples, and lens tissue (in children with ocular anomalies) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/29,97,101-103\">",
"     29,97,101-103",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Retrospective diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is difficult to establish a diagnosis of CRI in children older than one year of age [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/32,97\">",
"     32,97",
"    </a>",
"    ]. At this age, serologic testing usually is not diagnostic, and viral isolation is uncommon. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Virus isolation'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H19\">",
"     'Serology'",
"    </a>",
"    above.) .",
"   </p>",
"   <p>",
"    Retrospective diagnosis of congenital rubella syndrome may be possible in children who are older than one year through:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Detection of persistent rubella RNA by PCR.",
"     </li>",
"     <li>",
"      Measuring lymphocyte response to rubella in vitro [",
"      <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/40,104,105\">",
"       40,104,105",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Measuring rubella IgG avidity (strength of antigen-antibody binding); children with intrauterine rubella infection have low rubella-specific IgG avidity [",
"      <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/29,32,99,100,106\">",
"       29,32,99,100,106",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Measuring antibody response to rubella vaccination (in children with compatible manifestations but nondetectable antibody); children with congenital rubella syndrome generally do not respond to rubella vaccination [",
"      <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/29,31,35,40,41\">",
"       29,31,35,40,41",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Humoral response'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     MANDATED REPORTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cases of congenital rubella syndrome (CRS) (suspected or confirmed) in the United States should be reported to the Centers for Disease Control and Prevention through local and state health departments [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/94,95\">",
"     94,95",
"    </a>",
"    ]. These cases should be reported as soon as they are suspected, even if laboratory confirmation is pending. Cases of CRS indicate the presence of rubella infections in the community that may previously have been unrecognized and should trigger intensified surveillance for rubella and CRS [",
"    <a class=\"abstract\" href=\"UTD.htm?9/49/10010/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although additional information may be collected at the direction of the state health department, the report should include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Demographic information.",
"     </li>",
"     <li>",
"      Maternal history &ndash; Date of rubella vaccination(s); dates and results of previous serologic tests for rubella immunity; history or documentation of rubella infection during pregnancy; history of pregnancies inside and outside the United States; country of birth and length of residence in the United States; history of exposure to rubella; travel history.",
"     </li>",
"     <li>",
"      Clinical details (eg, cataracts, hearing impairment, developmental delay, type of congenital heart defect, meningoencephalitis, microcephaly).",
"     </li>",
"     <li>",
"      Types and results of laboratory testing performed on mother and child.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?14/10/14499?source=see_link\">",
"       \"Patient information: Rubella (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Congenital rubella infection (CRI) refers to all outcomes associated with intrauterine rubella infection, including asymptomatic infection. Congenital rubella syndrome (CRS) refers to variable constellations of birth defects (",
"      <a class=\"graphic graphic_table graphicRef55913 \" href=\"UTD.htm?38/56/39820\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Terminology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risk of maternal-fetal transmission and clinical manifestations of CRI vary with the timing of maternal infection. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathogenesis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/60/6087?source=see_link&amp;anchor=H6#H6\">",
"       \"Rubella in pregnancy\", section on 'Congenital rubella syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      CRI has a broad spectrum of clinical manifestations that may manifest throughout life (",
"      <a class=\"graphic graphic_table graphicRef75721 \" href=\"UTD.htm?15/35/15933\">",
"       table 2",
"      </a>",
"      ). Hearing loss, cataracts (",
"      <a class=\"graphic graphic_picture graphicRef64979 \" href=\"UTD.htm?37/11/38079\">",
"       picture 1",
"      </a>",
"      ), and cardiac disease are the classic manifestations of CRS (",
"      <a class=\"graphic graphic_table graphicRef55913 \" href=\"UTD.htm?38/56/39820\">",
"       table 1",
"      </a>",
"      ). However, rubella virus may infect virtually every fetal organ. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The possibility of CRI should be considered in any infant born to a woman who had documented or suspected rubella infection at any time during pregnancy, and any infant with intrauterine growth retardation or other clinical manifestations of CRS (",
"      <a class=\"graphic graphic_table graphicRef55913 \" href=\"UTD.htm?38/56/39820\">",
"       table 1",
"      </a>",
"      ), regardless of maternal history. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Clinical suspicion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The evaluation of a newborn with clinical findings compatible with CRS should include review of maternal history for evidence of rubella immunity, assessment of physical stigmata of CRS (",
"      <a class=\"graphic graphic_table graphicRef55913 \" href=\"UTD.htm?38/56/39820\">",
"       table 1",
"      </a>",
"      ), complete blood count and platelet count, radiographs of the long bones, ophthalmologic evaluation, audiologic evaluation, neuroimaging, and lumbar puncture. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of CRI is confirmed by isolation of rubella virus in culture, demonstration of rubella-specific IgM antibodies, demonstration of rubella-specific IgG antibodies that persist at a higher concentration or longer duration than expected from passive transfer of maternal antibody, or detection of rubella virus RNA by polymerase chain reaction (",
"      <a class=\"graphic graphic_table graphicRef55913 \" href=\"UTD.htm?38/56/39820\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Laboratory diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the United States, cases of CRS (suspected or confirmed) should be reported to the Centers for Disease Control and Prevention through local and state health departments. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Mandated reporting'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/1\">",
"      Reef SE, Plotkin S, Cordero JF, et al. Preparing for elimination of congenital Rubella syndrome (CRS): summary of a workshop on CRS elimination in the United States. Clin Infect Dis 2000; 31:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/2\">",
"      Centers for Disease Control and Prevention (CDC). Elimination of rubella and congenital rubella syndrome--United States, 1969-2004. MMWR Morb Mortal Wkly Rep 2005; 54:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/3\">",
"      Centers for Disease Control and Prevention (CDC). Progress toward elimination of rubella and congenital rubella syndrome--the Americas, 2003-2008. MMWR Morb Mortal Wkly Rep 2008; 57:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/4\">",
"      Centers for Disease Control and Prevention (CDC). Progress toward elimination of measles and prevention of congenital rubella infection--European region, 1990-2004. MMWR Morb Mortal Wkly Rep 2005; 54:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/5\">",
"      Reef SE, Cochi SL. The evidence for the elimination of rubella and congenital rubella syndrome in the United States: a public health achievement. Clin Infect Dis 2006; 43 Suppl 3:S123.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Rubella. In: Epidemiology and Prevention of Vaccine-Preventable Diseases. The Pink Book, 12th ed, Atkinson W, Wolfe S, Hamborsky J (Eds). Public Health Foundation, Washington, DC 2011. file://www.cdc.gov/vaccines/pubs/pinkbook/downloads/rubella.pdf (Accessed on August 10, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/7\">",
"      Katow S. Molecular epidemiology of rubella virus in Asia: utility for reduction in the burden of diseases due to congenital rubella syndrome. Pediatr Int 2004; 46:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/8\">",
"      Vijayalakshmi P, Anuradha R, Prakash K, et al. Rubella serosurveys at three Aravind Eye Hospitals in Tamil Nadu, India. Bull World Health Organ 2004; 82:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/9\">",
"      Gandhoke I, Aggarwal R, Lal S, Khare S. Seroprevalence and incidence of rubella in and around Delhi (1988-2002). Indian J Med Microbiol 2005; 23:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/10\">",
"      Gandhoke I, Aggarwal R, Lal S, Khare S. Rubella in Delhi: in-utero infection and congenital rubella syndrome. Indian J Med Microbiol 2008; 26:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/11\">",
"      Sadighi J, Eftekhar H, Mohammad K. Congenital rubella syndrome in Iran. BMC Infect Dis 2005; 5:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/12\">",
"      Bloom S, Rguig A, Berraho A, et al. Congenital rubella syndrome burden in Morocco: a rapid retrospective assessment. Lancet 2005; 365:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/13\">",
"      Malakmadze N, Zimmerman LA, Uzicanin A, et al. Development of a rubella vaccination strategy: contribution of a rubella susceptibility study of women of childbearing age in Kyrgyzstan, 2001. Clin Infect Dis 2004; 38:1780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/14\">",
"      Lanzieri TM, Parise MS, Siqueira MM, et al. Incidence, clinical features and estimated costs of congenital rubella syndrome after a large rubella outbreak in Recife, Brazil, 1999-2000. Pediatr Infect Dis J 2004; 23:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/15\">",
"      Webster WS. Teratogen update: congenital rubella. Teratology 1998; 58:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/16\">",
"      Woods WA, Johnson RT, Hostetler DD, et al. Immunofluorescent studies on rubella-infected tissue cultures and human tissues. J Immunol 1966; 96:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/17\">",
"      Rawls WE. Congenital rubella: the significance of virus persistence. Prog Med Virol 1968; 10:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/18\">",
"      Rorke LB, Spiro AJ. Cerebral lesions in congenital rubella syndrome. J Pediatr 1967; 70:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/19\">",
"      Miller E, Cradock-Watson JE, Pollock TM. Consequences of confirmed maternal rubella at successive stages of pregnancy. Lancet 1982; 2:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/20\">",
"      Cooper LZ. The history and medical consequences of rubella. Rev Infect Dis 1985; 7 Suppl 1:S2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/21\">",
"      Naeye RL, Blanc W. Pathogenesis of congenital rubella. JAMA 1965; 194:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/22\">",
"      Lee JY, Bowden DS. Rubella virus replication and links to teratogenicity. Clin Microbiol Rev 2000; 13:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/23\">",
"      PLOTKIN SA, BOUE A, BOUE JG. THE IN VITRO GROWTH OF RUBELLA VIRUS IN HUMAN EMBRYO CELLS. Am J Epidemiol 1965; 81:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/24\">",
"      Vaheri A, Cristofalo VJ. Metabolism of rubella virus-infected BHK 21 cells. Enhanced glycolysis and late cellular inhibition. Arch Gesamte Virusforsch 1967; 21:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/25\">",
"      Plotkin SA, Vaheri A. Human fibroblasts infected with rubella virus produce a growth inhibitor. Science 1967; 156:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/26\">",
"      Duncan R, Muller J, Lee N, et al. Rubella virus-induced apoptosis varies among cell lines and is modulated by Bcl-XL and caspase inhibitors. Virology 1999; 255:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/27\">",
"      Adamo P, As&iacute;s L, Silveyra P, et al. Rubella virus does not induce apoptosis in primary human embryo fibroblast cultures: a possible way of viral persistence in congenital infection. Viral Immunol 2004; 17:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/28\">",
"      Adamo MP, Zapata M, Frey TK. Analysis of gene expression in fetal and adult cells infected with rubella virus. Virology 2008; 370:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/29\">",
"      Banatvala JE, Brown DW. Rubella. Lancet 2004; 363:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/30\">",
"      Buimovici-Klein E, Lang PB, Ziring PR, Cooper LZ. Impaired cell-mediated immune response in patients with congenital rubella: correlation with gestational age at time of infection. Pediatrics 1979; 64:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/31\">",
"      Mauracher CA, Mitchell LA, Tingle AJ. Selective tolerance to the E1 protein of rubella virus in congenital rubella syndrome. J Immunol 1993; 151:2041.",
"     </a>",
"    </li>",
"    <li>",
"     Cherry JD. Rubella virus. In: Textbook of Pediatric Infectious Diseases, 6th, Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL (Eds), Saunders, Philadelphia 2009. p.2271.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/33\">",
"      Cradock-Watson JE, Ridehalgh MK. Specific immunoglobulins in infants with the congenital rubella syndrome. J Hyg (Lond) 1976; 76:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/34\">",
"      Peckham CS. Clinical and laboratory study of children exposed in utero to maternal rubella. Arch Dis Child 1972; 47:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/35\">",
"      Cooper LZ, Florman AL, Ziring PR, Krugman S. Loss of rubella hemagglutination inhibition antibody in congenital rubella. Failure of seronegative children with congenital rubella to respond to HPV-77 rubella vaccine. Am J Dis Child 1971; 122:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/36\">",
"      Kenrick KG, Slinn RF, Dorman DC, Menser MA. Immunoglobulins and rubella-virus antibodies in adults with congenital rubella. Lancet 1968; 1:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/37\">",
"      Hardy JB, Sever JL, Gilkeson MR. Declining antibody titers in children with congenital rubella. J Pediatr 1969; 75:213.",
"     </a>",
"    </li>",
"    <li>",
"     Plotkin, SA, Reef, SE, Cooper, LZ, Alford, CA. Rubella. In: Infectious Diseases of the Fetus and Newborn Infant, 7th ed, Remington, JS, Klein, JO, Wilson, CB, et al (Eds), Elsevier Saunders, Philadelphia 2011. p.861.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/39\">",
"      Plotkin SA, Klaus RM, Whitely JP. Hypogammaglobulinemia in an infant with congenital rubella syndrome; failure of 1-adamantanamine to stop irus excretion. J Pediatr 1966; 69:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/40\">",
"      Hosking CS, Pyman C, Wilkins B. The nerve deaf child--intrauterine rubella or not? Arch Dis Child 1983; 58:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/41\">",
"      Meitsch K, Enders G, Wolinsky JS, et al. The role of rubella-immunoblot and rubella-peptide-EIA for the diagnosis of the congenital rubella syndrome during the prenatal and newborn periods. J Med Virol 1997; 51:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/42\">",
"      Verder H, Dickmeiss E, Haahr S, et al. Late-onset rubella syndrome: coexistence of immune complex disease and defective cytotoxic effector cell function. Clin Exp Immunol 1986; 63:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/43\">",
"      Rabinowe SL, George KL, Loughlin R, et al. Congenital rubella. Monoclonal antibody-defined T cell abnormalities in young adults. Am J Med 1986; 81:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/44\">",
"      Olson GB, South MA, Good RA. Phytohaemagglutinin unresponsiveness of lymphocytes from babies with congenital rubella. Nature 1967; 214:695.",
"     </a>",
"    </li>",
"    <li>",
"     Maldonado YA. Rubella virus. In: Principles and Practice of Pediatric Infectious Diseases, 4th, Long SS, Pickering LK, Prober CG.  (Eds), Elsevier Saunders, Edinburgh 2012. p.1112.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/46\">",
"      Ginsberg-Fellner F, Witt ME, Fedun B, et al. Diabetes mellitus and autoimmunity in patients with the congenital rubella syndrome. Rev Infect Dis 1985; 7 Suppl 1:S170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/47\">",
"      Viskari H, Paronen J, Keskinen P, et al. Humoral beta-cell autoimmunity is rare in patients with the congenital rubella syndrome. Clin Exp Immunol 2003; 133:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/48\">",
"      Gale EA. Congenital rubella: citation virus or viral cause of type 1 diabetes? Diabetologia 2008; 51:1559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/49\">",
"      Rubinstein P, Walker ME, Fedun B, et al. The HLA system in congenital rubella patients with and without diabetes. Diabetes 1982; 31:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/50\">",
"      Menser MA, Forrest JM, Bransby RD. Rubella infection and diabetes mellitus. Lancet 1978; 1:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/51\">",
"      Hy&ouml;ty H, Taylor KW. The role of viruses in human diabetes. Diabetologia 2002; 45:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/52\">",
"      Ou D, Jonsen LA, Metzger DL, Tingle AJ. CD4+ and CD8+ T-cell clones from congenital rubella syndrome patients with IDDM recognize overlapping GAD65 protein epitopes. Implications for HLA class I and II allelic linkage to disease susceptibility. Hum Immunol 1999; 60:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/53\">",
"      Givens KT, Lee DA, Jones T, Ilstrup DM. Congenital rubella syndrome: ophthalmic manifestations and associated systemic disorders. Br J Ophthalmol 1993; 77:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/54\">",
"      Gregg N. Congenital cataract following German measles in the mother. Trans Ophthalmol Soc Austr 1941; 3:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/55\">",
"      GREGG NM. Congenital defects associated with maternal rubella. Aust Hosp 1947; 14:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/56\">",
"      Cooper LZ, Krugman S. Clinical manifestations of postnatal and congenital rubella. Arch Ophthalmol 1967; 77:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/57\">",
"      Cradock-Watson JE, Ridehalgh MK, Anderson MJ, et al. Fetal infection resulting from maternal rubella after the first trimester of pregnancy. J Hyg (Lond) 1980; 85:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/58\">",
"      Peckham C. Congenital rubella in the United Kingdom before 1970: the prevaccine era. Rev Infect Dis 1985; 7 Suppl 1:S11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/59\">",
"      Grillner L, Forsgren M, Barr B, et al. Outcome of rubella during pregnancy with special reference to the 17th-24th weeks of gestation. Scand J Infect Dis 1983; 15:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/60\">",
"      Enders G, Nickerl-Pacher U, Miller E, Cradock-Watson JE. Outcome of confirmed periconceptional maternal rubella. Lancet 1988; 1:1445.",
"     </a>",
"    </li>",
"    <li>",
"     Schiff GM, Sutherland J, Light I. Congenital rubella. In: Prenatal Infections. International Symposium of Vienna, Thalhammer O (Ed), Georg Thieme Verlag, Stuttgart 1971. p.31.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/62\">",
"      Forrest JM, Turnbull FM, Sholler GF, et al. Gregg's congenital rubella patients 60 years later. Med J Aust 2002; 177:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/63\">",
"      McIntosh ED, Menser MA. A fifty-year follow-up of congenital rubella. Lancet 1992; 340:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/64\">",
"      Menser MA, Dods L, Harley JD. A twenty-five-year follow-up of congenital rubella. Lancet 1967; 2:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/65\">",
"      Cooper LZ, Ziring PR, Ockerse AB, et al. Rubella. Clinical manifestations and management. Am J Dis Child 1969; 118:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/66\">",
"      Oster ME, Riehle-Colarusso T, Correa A. An update on cardiovascular malformations in congenital rubella syndrome. Birth Defects Res A Clin Mol Teratol 2010; 88:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/67\">",
"      Sever JL, South MA, Shaver KA. Delayed manifestations of congenital rubella. Rev Infect Dis 1985; 7 Suppl 1:S164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/68\">",
"      Fortuin NJ, Morrow AG, Roberts WC. Late vascular manifestations of the rubella syndrome. A roentgenographic-pathologic study. Am J Med 1971; 51:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/69\">",
"      Desmond MM, Fisher ES, Vorderman AL, et al. The longitudinal course of congenital rubella encephalitis in nonretarded children. J Pediatr 1978; 93:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/70\">",
"      Anderson H, Barr B, Wedenberg E. Genetic disposition--a prerequisite for maternal rubella deafness. Arch Otolaryngol 1970; 91:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/71\">",
"      Forrest JM, Menser MA, Burgess JA. High frequency of diabetes mellitus in young adults with congenital rubella. Lancet 1971; 2:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/72\">",
"      Shaver KA, Boughman JA, Nance WE. Congenital rubella syndrome and diabetes: a review of epidemiologic, genetic, and immunologic factors. Am Ann Deaf 1985; 130:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/73\">",
"      Fine PE, Adelstein AM, Snowman J, et al. Long term effects of exposure to viral infections in utero. Br Med J (Clin Res Ed) 1985; 290:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/74\">",
"      Takasu N, Ikema T, Komiya I, Mimura G. Forty-year observation of 280 Japanese patients with congenital rubella syndrome. Diabetes Care 2005; 28:2331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/75\">",
"      AvRuskin TW, Brakin M, Juan C. Congenital rubella and myxedema. Pediatrics 1982; 69:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/76\">",
"      Ziring PR, Fedun BA, Cooper LZ. Letter: Thyrotoxicosis in congenital rubella. J Pediatr 1975; 87:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/77\">",
"      Ziring PR, Gallo G, Finegold M, et al. Chronic lymphocytic thyroiditis: identification of rubella virus antigen in the thyroid of a child with congenital rubella. J Pediatr 1977; 90:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/78\">",
"      Nieburg PI, Gardner LI. Letter: Thyroiditis and congenital rubella syndrome. J Pediatr 1976; 89:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/79\">",
"      Comas AP. Letter: Congenital rubella and acquired hypothyroidism secondary to Hashimoto thyroiditis. J Pediatr 1976; 88:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/80\">",
"      Preece MA, Kearney PJ, Marshall WC. Growth-hormone deficiency in congenital rubella. Lancet 1977; 2:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/81\">",
"      Duszak RS. Congenital rubella syndrome--major review. Optometry 2009; 80:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/82\">",
"      O'Neill JF. The ocular manifestations of congenital infection: a study of the early effect and long-term outcome of maternally transmitted rubella and toxoplasmosis. Trans Am Ophthalmol Soc 1998; 96:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/83\">",
"      Weil ML, Itabashi H, Cremer NE, et al. Chronic progressive panencephalitis due to rubella virus simulating subacute sclerosing panencephalitis. N Engl J Med 1975; 292:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/84\">",
"      Townsend JJ, Baringer JR, Wolinsky JS, et al. Progressive rubella panencephalitis. Late onset after congenital rubella. N Engl J Med 1975; 292:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/85\">",
"      Ameratunga R, Woon ST, Koopmans W, French J. Cellular and molecular characterisation of the hyper immunoglobulin M syndrome associated with congenital rubella infection. J Clin Immunol 2009; 29:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/86\">",
"      Palacin PS, Castilla Y, Garz&oacute;n P, et al. Congenital rubella syndrome, hyper-IgM syndrome and autoimmunity in an 18-year-old girl. J Paediatr Child Health 2007; 43:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/87\">",
"      Plotkin SA, Cochran W, Lindquist JM, et al. Congenital rubella syndrome in late infancy. JAMA 1967; 200:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/88\">",
"      Cooper LZ, Krugman S. Diagnosis and management: congenital rubella. Pediatrics 1966; 37:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/89\">",
"      Lindquist JM, Plotkin SA, Shaw L, et al. Congenital rubella syndrome as a systemic infection. Studies of affected infants born in Philadelphia, U.S.A. Br Med J 1965; 2:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/90\">",
"      Shewmon DA, Cherry JD, Kirby SE. Shedding of rubella virus in a 4 1/2-year-old boy with congenital rubella. Pediatr Infect Dis 1982; 1:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/91\">",
"      Rawls WE, Phillips A, Melnick JL, Desmond MM. Persistent virus infection in congenital rubella. Arch Ophthalmol 1967; 77:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/92\">",
"      Menser MA, Harley JD, Hertzberg R, et al. Persistence of virus in lens for three years after prenatal rubella. Lancet 1967; 2:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/93\">",
"      PHILLIPS CA, MELNICK JL, YOW MD, et al. PERSISTENCE OF VIRUS IN INFANTS WITH CONGENITAL RUBELLA AND IN NORMAL INFANTS WITH A HISTORY OF MATERNAL RUBELLA. JAMA 1965; 193:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/94\">",
"      Control and prevention of rubella: evaluation and management of suspected outbreaks, rubella in pregnant women, and surveillance for congenital rubella syndrome. MMWR Recomm Rep 2001; 50:1.",
"     </a>",
"    </li>",
"    <li>",
"     Rubella, congenital syndrome. 2007 case definition. file://www.cdc.gov/osels/ph_surveillance/nndss/casedef/rubellasc2007.htm (Accessed on August 31, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/96\">",
"      Nickerson JP, Richner B, Santy K, et al. Neuroimaging of pediatric intracranial infection--part 2: TORCH, viral, fungal, and parasitic infections. J Neuroimaging 2012; 22:e52.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Rubella. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LK.  (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.629.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/98\">",
"      Dimech W, Panagiotopoulos L, Marler J, et al. Evaluation of three immunoassays used for detection of anti-rubella virus immunoglobulin M antibodies. Clin Diagn Lab Immunol 2005; 12:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/99\">",
"      Fuccillo DA, Steele RW, Hensen SA, et al. Impaired cellular immunity to rubella virus in congenital rubella. Infect Immun 1974; 9:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/100\">",
"      Herne V, Hedman K, Reedik P. Immunoglobulin G avidity in the serodiagnosis of congenital rubella syndrome. Eur J Clin Microbiol Infect Dis 1997; 16:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/101\">",
"      Rajasundari TA, Sundaresan P, Vijayalakshmi P, et al. Laboratory confirmation of congenital rubella syndrome in infants: an eye hospital based investigation. J Med Virol 2008; 80:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/102\">",
"      Revello MG, Baldanti F, Sarasini A, et al. Prenatal diagnosis of rubella virus infection by direct detection and semiquantitation of viral RNA in clinical samples by reverse transcription-PCR. J Clin Microbiol 1997; 35:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/103\">",
"      Bosma TJ, Corbett KM, O'Shea S, et al. PCR for detection of rubella virus RNA in clinical samples. J Clin Microbiol 1995; 33:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/104\">",
"      O'Shea S, Best J, Banatvala JE. A lymphocyte transformation assay for the diagnosis of congenital rubella. J Virol Methods 1992; 37:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/105\">",
"      Iuorio JL, Hosking CS, Pyman C. Retrospective diagnosis of congenital rubella. Br Med J (Clin Res Ed) 1984; 289:1566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/49/10010/abstract/106\">",
"      Thomas HI, Morgan-Capner P, Cradock-Watson JE, et al. Slow maturation of IgG1 avidity and persistence of specific IgM in congenital rubella: implications for diagnosis and immunopathology. J Med Virol 1993; 41:196.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6047 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-199.231.185.123-63BADDD788-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_49_10010=[""].join("\n");
var outline_f9_49_10010=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      IMMUNOLOGIC RESPONSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Humoral response",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H40076903\">",
"      - Lack of booster response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Cellular response",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H40076910\">",
"      - Possible role in autoimmunity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      In neonates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      In infants and children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Late manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28489670\">",
"      - Hearing loss",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28489677\">",
"      - Endocrine disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28489684\">",
"      - Eye problems",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28489691\">",
"      - Vascular effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28489698\">",
"      - Panencephalitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28489705\">",
"      - Immune defects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Viral shedding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H263857150\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      EVALUATION AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Clinical suspicion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Laboratory diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Virus isolation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Serology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Rubella virus PCR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Retrospective diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      MANDATED REPORTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6047\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6047|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/22/17775\" title=\"figure 1\">",
"      Rubella CRS epidemiology US",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6047|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/11/38079\" title=\"picture 1\">",
"      Congenital rubella cataract",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/51/6967\" title=\"picture 2\">",
"      Cong rubella retinopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/32/34305\" title=\"picture 3\">",
"      Blueberry muffin lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6047|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/56/39820\" title=\"table 1\">",
"      CRS case definition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/35/15933\" title=\"table 2\">",
"      Congenital rubella ssx",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/26/33196\" title=\"table 3\">",
"      Characteristic features of congenital infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21865?source=related_link\">",
"      Acquired hypothyroidism in childhood and adolescence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22761?source=related_link\">",
"      Cataract in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/29/7641?source=related_link\">",
"      Clinical manifestations and diagnosis of hyperthyroidism in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/52/35656?source=related_link\">",
"      Clinical manifestations and diagnosis of patent ductus arteriosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/44/33482?source=related_link\">",
"      Congenital heart disease (CHD) in the newborn: Presentation and screening for critical CHD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36855?source=related_link\">",
"      Congenital rubella syndrome: Management, outcome, and prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/31/17914?source=related_link\">",
"      Congenital syphilis: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/12/43208?source=related_link\">",
"      Congenital toxoplasmosis: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/5/82?source=related_link\">",
"      Diagnosis of growth hormone deficiency in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/38/19050?source=related_link\">",
"      Etiology of hearing impairment in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44344?source=related_link\">",
"      Evaluation of hearing impairment in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/31/35321?source=related_link\">",
"      Neonatal herpes simplex virus infection: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/0/21512?source=related_link\">",
"      Neonatal pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/24/28041?source=related_link\">",
"      Overview of TORCH infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/31/41463?source=related_link\">",
"      Overview of glaucoma in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23210?source=related_link\">",
"      Pathogenesis of type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/27/13752?source=related_link\">",
"      Pathophysiology, clinical features, and diagnosis of tetralogy of Fallot",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/10/14499?source=related_link\">",
"      Patient information: Rubella (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/57/5016?source=related_link\">",
"      Primary infantile glaucoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/14/26855?source=related_link\">",
"      Rubella",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/60/6087?source=related_link\">",
"      Rubella in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38345?source=related_link\">",
"      Valvar aortic stenosis in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_49_10011="Benefits activity PI";
var content_f9_49_10011=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F72243&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F72243&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Benefits of regular physical activity",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Reduces the risk of dying prematurely",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reduces the risk of dying from heart disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reduces the risk of stroke",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reduces the risk of developing diabetes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reduces the risk of developing high blood pressure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Helps reduce blood pressure in people who already have high blood pressure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reduces the risk of developing colon cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reduces feelings of depression and anxiety",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Helps control weight",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Helps build and maintain healthy bones, muscles and joints",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Helps older adults become stronger and better able to move about without falling",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Promotes psychological well-being",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_49_10011=[""].join("\n");
var outline_f9_49_10011=null;
var title_f9_49_10012="Bone penetration for selected antibiotics";
var content_f9_49_10012=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F53786&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F53786&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Bone penetration for selected antibiotics",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Antibiotic",
"       </td>",
"       <td class=\"subtitle1\">",
"        Range of mean bone to serum concentration ratios",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Levofloxacin",
"       </td>",
"       <td>",
"        0.36-1.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ciprofloxacin",
"       </td>",
"       <td>",
"        0.27-1.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Moxifloxacin",
"       </td>",
"       <td>",
"        0.33-1.05",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vancomycin",
"       </td>",
"       <td>",
"        0.05-0.67",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Linezolid",
"       </td>",
"       <td>",
"        0.2-0.51",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Daptomycin",
"       </td>",
"       <td>",
"        1.17*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clindamycin",
"       </td>",
"       <td>",
"        0.21-0.45",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cefazolin",
"       </td>",
"       <td>",
"        0.179",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ceftriaxone",
"       </td>",
"       <td>",
"        0.07-0.17",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cefuroxime",
"       </td>",
"       <td>",
"        0.04-0.55",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rifampin (rifampicin)",
"       </td>",
"       <td>",
"        0.08-0.57",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Numerous factors account for a wide range of bone to serum concentration ratios reported, including variation in timing/technique of sampling, analytical method, and condition of bone.",
"    <div class=\"footnotes\">",
"     * Data are limited to a case series of nine diabetic patients with foot infection and osteomyelitis.",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <ol>",
"       <li>",
"        Landersdorfer CB, Bulitta JB, Kinzig M, et al. Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations. Clin Pharmacokinet 2009; 48:89.",
"       </li>",
"       <li>",
"        von Baum H, B&ouml;ttcher S, Abel R, et al. Tissue and serum concentrations of levofloxacin in orthopaedic patients. Int J Antimicrob Agents 2001; 18:335.",
"       </li>",
"       <li>",
"        Garazzino S, Aprato, A, Baietto, L, et al. Glycopeptide bone penetration in patients with septic pseudoarthrosis of the tibia. Clin Pharmacokinet 2008; 47:793.",
"       </li>",
"       <li>",
"        Traunmuller F, Schintler MV, Metzler J, et al. Soft tissue and bone penetration abilities of daptomycin in diabetic patients with bacterial foot infections. J Antimicrob Chemother 2010; 65:1252.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_49_10012=[""].join("\n");
var outline_f9_49_10012=null;
var title_f9_49_10013="Specimens for anthrax testing";
var content_f9_49_10013=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F65814&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F65814&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=11\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Acceptable biological specimens needed for laboratory testing for anthrax",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Types of tests",
"       </td>",
"       <td class=\"subtitle1\">",
"        Acceptable materials",
"       </td>",
"       <td class=\"subtitle1\">",
"        Minimum amount or size",
"       </td>",
"       <td class=\"subtitle1\">",
"        Transport &le;2h",
"       </td>",
"       <td class=\"subtitle1\">",
"        Transport &ge;2h",
"       </td>",
"       <td class=\"subtitle1\">",
"        Do not send",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" rowspan=\"9\">",
"        Culture and PCR",
"       </td>",
"       <td>",
"        Isolate",
"       </td>",
"       <td>",
"        Plate, slant",
"       </td>",
"       <td>",
"        RT",
"       </td>",
"       <td>",
"        RT",
"       </td>",
"       <td>",
"        Broth",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Swabs (lesion)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        RT",
"       </td>",
"       <td>",
"        RT",
"       </td>",
"       <td>",
"        On transport medium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blood, whole",
"       </td>",
"       <td>",
"        1.0 mL in EDTA or sodium citrate tubes (do not use heparin)",
"       </td>",
"       <td>",
"        RT",
"       </td>",
"       <td>",
"        2 to 8&deg;C",
"       </td>",
"       <td>",
"        Blood culture bottle or heparin tube",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluids/aspirate (pleural, bronchial, CSF)",
"       </td>",
"       <td>",
"        0.5 mL",
"       </td>",
"       <td>",
"        RT",
"       </td>",
"       <td>",
"        2 to 8&deg;C",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tissue, fresh",
"       </td>",
"       <td>",
"        5 mm",
"        <sup>",
"         3",
"        </sup>",
"        in container",
"       </td>",
"       <td>",
"        2 to 8&deg;C",
"       </td>",
"       <td>",
"        Frozen at",
"        <br/>",
"        -70&deg;C",
"       </td>",
"       <td>",
"        Preserved tissue",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Blood clot",
"       </td>",
"       <td>",
"        1.0 mL clot",
"       </td>",
"       <td>",
"        RT",
"       </td>",
"       <td>",
"        2 to 8&deg;C",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serum, separated and removed from clot",
"       </td>",
"       <td>",
"        1.0 mL",
"       </td>",
"       <td>",
"        RT",
"       </td>",
"       <td>",
"        2 to 8&deg;C",
"       </td>",
"       <td>",
"        Frozen serum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Citrated plasma, separated and removed from clot",
"       </td>",
"       <td>",
"        1.0 mL",
"       </td>",
"       <td>",
"        RT",
"       </td>",
"       <td>",
"        2 to 8&deg;C",
"       </td>",
"       <td>",
"        Frozen plasma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stool",
"       </td>",
"       <td>",
"        &ge;5 g",
"       </td>",
"       <td>",
"        2 to 8&deg;C",
"       </td>",
"       <td>",
"        2 to 8&deg;C",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" rowspan=\"2\">",
"        Serology",
"       </td>",
"       <td>",
"        Serum, separated and removed from clot",
"       </td>",
"       <td>",
"        1.0 mL",
"       </td>",
"       <td>",
"        2 to 8&deg;C",
"       </td>",
"       <td>",
"        Frozen at",
"        <br/>",
"        &lt;-20&deg;C",
"       </td>",
"       <td>",
"        Whole blood or blood culture bottle or plasma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Citrated plasma, separated and removed from clot",
"       </td>",
"       <td>",
"        1.0 mL",
"       </td>",
"       <td>",
"        2 to 8&deg;C",
"       </td>",
"       <td>",
"        Frozen at",
"        <br/>",
"        &lt;-20&deg;C",
"       </td>",
"       <td>",
"        Plasma from EDTA or heparin tube",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" rowspan=\"2\">",
"        Histopathology",
"       </td>",
"       <td>",
"        Tissues, preserved in 10 percent buffered formalin",
"       </td>",
"       <td>",
"        1.0 cm",
"        <sup>",
"         3",
"        </sup>",
"       </td>",
"       <td>",
"        RT",
"       </td>",
"       <td>",
"        RT",
"       </td>",
"       <td>",
"        Fresh or frozen tissue",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Biopsies of lesions, (eg, skin), preserved in 10 percent buffered  formalin",
"       </td>",
"       <td>",
"        0.3 mm diameter",
"       </td>",
"       <td>",
"        RT",
"       </td>",
"       <td>",
"        RT",
"       </td>",
"       <td>",
"        Fresh or frozen tissue",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     RT: room temperature; EDTA: ethylenediaminetetraacetic acid; CSF: cerebrospinal fluid.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_49_10013=[""].join("\n");
var outline_f9_49_10013=null;
var title_f9_49_10014="Paclitaxel and carboplatin for NSCLC";
var content_f9_49_10014=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F56125&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F56125&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Paclitaxel and carboplatin chemotherapy for non-small cell lung cancer",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr class=\"divider_bottom\">",
"       <td colspan=\"4\">",
"        Cycle length: Every 21 days, for a maximum of six cycles.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose and route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Given on days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Paclitaxel",
"        </strong>",
"       </td>",
"       <td>",
"        200 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in 250 mL normal saline (NS) and administer over one hour; special tubinig needed*.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Carboplatin",
"        </strong>",
"       </td>",
"       <td>",
"        AUC",
"        <sup>",
"         &Delta;",
"        </sup>",
"        = 6 mg/mL x min IV",
"       </td>",
"       <td>",
"        Dilute in 250 mL NS",
"        <sup>",
"         &loz;",
"        </sup>",
"        and administer over 30 minutes.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Pretreatment considerations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Emesis risk:",
"        </strong>",
"        MODERATE. Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Prophylaxis for infusion reactions:",
"        </strong>",
"        Premedicate with dexamethasone plus both an H1 and an H2 receptor antagonist prior to paclitaxel administration. Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Vesicant/irritant properties:",
"        </strong>",
"        Paclitaxel can cause significant tissue damage; avoid extravasation. Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-neoplastic vesicants\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Infection prophylaxis:",
"        </strong>",
"        Primary prophylaxis with hematopoietic growth factors is not recommended (risk of febrile neutropenia approximately 2 to 4 percent",
"        <sup>",
"         [1]",
"        </sup>",
"        ). Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for baseline liver or renal dysfunction:",
"        </strong>",
"        A lower starting dose of paclitaxel may be needed in patients with liver impairment. Each carboplatin dose should be calculated based upon renal function by use of the Calvert formula",
"        <sup>",
"         &Delta;",
"        </sup>",
"        . Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Monitoring parameters:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; CBC with differential weekly during treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Serum electrolytes and liver and renal function tests prior to each treatment cycle.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess changes in neurologic function prior to each treatment cycle.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Suggested dose alterations for toxicity:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Myelotoxicity/neurologic toxicity:",
"        </strong>",
"        Treatment with paclitaxel and carboplatin should be delayed until the absolute neutrophil count is greater than 1500/mm",
"        <sup>",
"         3",
"        </sup>",
"        and platelet count is greater than 100,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        . If a patient developed severe neutropenia (less than 500/mm",
"        <sup>",
"         3",
"        </sup>",
"        ) for a week or longer, or febrile neutropenia during the prior course, then the paclitaxel and carboplatin doses should be reduced by 20 to 25 percent for subsequent courses",
"        <sup>",
"         [2]",
"        </sup>",
"        . An alternative to dose reduction is the institution of hematopoietic growth factor support. The carboplatin dose should be decreased by 25 percent in patients whose platelet count nadir is less than 50,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        for longer than five days",
"        <sup>",
"         [3]",
"        </sup>",
"        . For patients who develop severe neuropathy (grade 3 or 4) for a week or longer, then the dose of paclitaxel should be reduced by 20 percent for subsequent courses",
"        <sup>",
"         [4]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Renal/hepatic toxicity:",
"        </strong>",
"        Alterations in renal function during therapy may require a recalculation of the carboplatin dose. Paclitaxel dose may need to be adjusted for hepatic impairment on day 1 of each cycle. Refer to UpToDate topics on \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\" and \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Neurotoxicity:",
"        </strong>",
"        The development of severe symptomatic peripheral neuropathy requires a dose reduction of 20 percent for all subsequent courses of paclitaxel",
"        <sup>",
"         [4]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         If there is a change in body weight of at least 10 percent, dose recalculation for both drugs should be considered.",
"        </strong>",
"        Dose reductions may also be indicated if there are other grade 2 or higher nonhematologic toxicities. The dose reduction is at the discretion of the clinician, as formal guidelines are not available.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"    </strong>",
"    <div class=\"footnotes\">",
"     IV: intravenous; CBC: complete blood count; GFR: glomerular filtration rate.",
"     <br/>",
"     * Paclitaxel can be administered in NS, 5 percent dextrose in water (D5W), or NS/D5W at varying concentrations between 0.3 to 1.2 mg/mL. Use glass or polypropylene bottles or polypropylene or polyolefin plastic bags, and administer through polyethylene-lined administration sets with a microporous membrane 0.22 microns or less.",
"     <br/>",
"     &Delta; AUC (area under the concentration X time curve) is converted to a patient-specific carboplatin dose (in mg) according to renal function by using the Calvert formula. The Calvert formula is total dose (mg) = (target AUC) x (GFR + 25). If using measured serum creatinine, limit the maximal GFR for the calculation to 125 mL/min. Refer to UpToDate topic on \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Sandler A, et al. N Engl J Med 2006; 355:2542.",
"      </li>",
"      <li>",
"       Langer CT, et al. J Clin Oncol 1995; 13:1860.",
"      </li>",
"      <li>",
"       Carboplatin injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 14, 2011).",
"      </li>",
"      <li>",
"       Taxol (paclitaxel) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on December 14, 2011).",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_49_10014=[""].join("\n");
var outline_f9_49_10014=null;
var title_f9_49_10015="Herpes zoster rash 2 PI";
var content_f9_49_10015=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F66249&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F66249&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Shingles (herpes zoster)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 350px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Vaibhav Parekh, MD, MBA.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_49_10015=[""].join("\n");
var outline_f9_49_10015=null;
